



# BMJ Open Approaches for combining primary care electronic health record data from multiple sources: a systematic review of observational studies

Daniel Dedman <sup>1,2</sup>, Melissa Cabecinha <sup>3</sup>, Rachael Williams,<sup>1</sup> Stephen J W Evans,<sup>4</sup> Krishnan Bhaskaran,<sup>2</sup> Ian J Douglas<sup>2</sup>

**To cite:** Dedman D, Cabecinha M, Williams R, *et al*. Approaches for combining primary care electronic health record data from multiple sources: a systematic review of observational studies. *BMJ Open* 2020;**10**:e037405. doi:10.1136/bmjopen-2020-037405

► Prepublication history and additional material for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-037405>).

Received 31 January 2020  
Revised 15 June 2020  
Accepted 14 August 2020



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

<sup>1</sup>Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London, UK

<sup>2</sup>Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK

<sup>3</sup>Research Department of Primary Care and Population Health, University College London, London, UK

<sup>4</sup>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK

## Correspondence to

Daniel Dedman;  
Daniel.Dedman@mhra.gov.uk

## ABSTRACT

**Objective** To identify observational studies which used data from more than one primary care electronic health record (EHR) database, and summarise key characteristics including: objective and rationale for using multiple data sources; methods used to manage, analyse and (where applicable) combine data; and approaches used to assess and report heterogeneity between data sources.

**Design** A systematic review of published studies.

**Data sources** Pubmed and Embase databases were searched using list of named primary care EHR databases; supplementary hand searches of reference list of studies were retained after initial screening.

**Study selection** Observational studies published between January 2000 and May 2018 were selected, which included at least two different primary care EHR databases.

**Results** 6054 studies were identified from database and hand searches, and 109 were included in the final review, the majority published between 2014 and 2018. Included studies used 38 different primary care EHR data sources. Forty-seven studies (44%) were descriptive or methodological. Of 62 analytical studies, 22 (36%) presented separate results from each database, with no attempt to combine them; 29 (48%) combined individual patient data in a one-stage meta-analysis and 21 (34%) combined estimates from each database using two-stage meta-analysis. Discussion and exploration of heterogeneity was inconsistent across studies.

**Conclusions** Comparing patterns and trends in different populations, or in different primary care EHR databases from the same populations, is important and a common objective for multi-database studies. When combining results from several databases using meta-analysis, provision of separate results from each database is helpful for interpretation. We found that these were often missing, particularly for studies using one-stage approaches, which also often lacked details of any statistical adjustment for heterogeneity and/or clustering. For two-stage meta-analysis, a clear rationale should be provided for choice of fixed effect and/or random effects or other models.

## INTRODUCTION

Multi-database observational studies are increasingly common. They are conducted

## Strengths and limitations of this study

- Our systematic review identified the increasing number of published observational studies, which specifically used primary care electronic health record (EHR) data from two or more sources.
- There were no restrictions on study design, exposures or outcomes.
- In the absence of relevant Medical Subject Heading terms, the search strategy relied on an extensive list of named primary care EHR databases to achieve as comprehensive coverage as possible.
- The selected publications were independently reviewed by two researchers.
- The findings of this review may not apply to multi-database studies, which did not use primary care EHR data sources.

for two main reasons: to compare results across diverse populations and healthcare settings, or to combine the data to increase statistical power. Primary care electronic health record (EHR) databases are particularly valuable because they provide longitudinal data on individuals, often over many years, and typically contain richer information on a broader range of exposures, risk factors and health outcomes than administrative databases.<sup>1–3</sup> Although individual primary care EHR databases are often relatively small, covering a single region or other national population subset, their growing availability in recent years is likely to further increase the importance of non-interventional studies, which combine these databases. Guidelines identifying best practice in this context have yet to be established but would be of clear benefit for researchers working with multiple databases. An important preliminary step is to describe current practice, but there is no comprehensive summary of studies which



used two or more primary care EHR databases, and the methods for combining them.

One previous systematic review focused on multi-database pharmacoepidemiology studies with a pre-planned approach to combine data to evaluate drug-outcome associations.<sup>4</sup> In that review, studies were not limited according to the types of databases used, but descriptive studies and those which did not combine results from different databases were excluded. The authors found that for data management arrangements, analysis of heterogeneity and methods for combining data reporting were often inadequate, making interpretation of study results more challenging. Since the focus of that review was pharmacoepidemiology studies and a wide range of database types, a broader view of combined primary care EHR data for any study purpose remains lacking.

The aim of this systematic review was to identify and describe the full range of completed studies which brought together primary care EHR data from two or more sources. The specific objectives were to summarise key study characteristics, including the main reasons or motivations for including data from different EHR databases; to describe the methods used to manage, analyse and (where applicable) combine data; and describe the approaches used to assess and report heterogeneity between primary care EHR data sources.

## METHODS

The review considered all multi-database studies, published in English language between 2000 and 2018, and which included at least two different primary care EHR databases or data sources, irrespective of whether other types of database were also included. Primary care EHR data was defined as data collected by primary care clinicians and related staff for the purpose of diagnosis, treatment, management and delivery of care of individual patients, and could include information contributed by other care providers.<sup>5</sup> It excluded data generated primarily for administrative purposes such as health insurance claims data, where the motivation for recording is different. Primary care EHR databases were considered irrespective of whether they were 'vertically' linked (ie, linked at the individual patient level) to another data source such as a disease registry or dispensing database. Each 'vertically' linked primary care EHR database was treated as a single data source. Apart from the specific focus on primary care EHR databases, no other restrictions were applied in terms of populations, geography, study period, exposure, outcome or study design.

A previous systematic review highlighted the challenge of identifying multi-database studies, for which no specific Medical Subject Heading (MeSH) terms exist.<sup>4</sup> An alternative approach was, therefore, used, based on a comprehensive list of named primary care EHR databases compiled from two online registers<sup>6,7</sup> and one systematic review of primary care data

collection projects.<sup>8</sup> For each named database, a keyword search was generated and run on Medline, and the results combined. Abstracts of published studies identified in this search were scanned for additional terms and phrases, which might be used to describe the primary care EHR data sources, and from these additional keyword searches were generated. The final search strategy (see online supplemental material) was used to identify studies in Medline and Embase databases published between January 2000 and May 2018.

Titles and abstracts of all retrieved studies were screened for eligibility by one reviewer (DD). A random 20% sample was also screened by a second reviewer (MC) and showed very good agreement between the two. Reference lists of papers selected for full review were hand searched for additional studies.

Full text was obtained for all papers selected during the initial screening, and read by two reviewers (DD and MC), who independently completed the final eligibility assessment and data extraction. Each reviewer extracted standardised information from the study publication and online supplemental materials (where available), which was entered into the review database (Microsoft Access) via electronic data collection form developed by one of the reviewers (DD), and pilot tested with seven studies. Information extracted included data sources used, main objectives, study design, study populations, exposure, comparators and outcomes, data management arrangements and statistical methods. All discordant results were reviewed, and the final designation agreed by both reviewers. No additional information was sought from investigators.

Studies were classified as analytical if they estimated an exposure–outcome association, or descriptive otherwise. We noted whether and how between-database heterogeneity was assessed, how this informed the decision to combine the data and whether a one-stage meta-analysis of pooled individual patient data (IPD) or two-stage meta-analysis of study-specific effect estimates was used, as well as choice of fixed-effects (FE) versus random-effects (RE) models. A clear rationale for using multiple data sources was not always stated, but in some instances could be inferred. For analytical studies where results were combined using one-stage or two-stage meta-analysis, unless stated otherwise the rationale was assumed to be an increase in the statistical precision of the exposure–outcome effect estimate. Three main models for data management and analysis were considered, based on previous reviews<sup>4,9–11</sup>: a fully centralised model for management and analysis of the raw data provided by each contributing database; a fully distributed model where all data management and analysis was undertaken locally, and only fully aggregated results were shared; and a partially distributed model with local extraction and data management to generate standardised patient level or partially aggregated datasets

in standardised format, which were then shared for final centralised analysis. Partially aggregated (or semi-aggregated) data summarise information on more than one individual (thereby enhancing privacy protection) while still allowing the pooling of data across databases for further analysis, including one-stage meta-analysis. Examples include total person time and event counts for groups of patients sharing the same characteristics.

We noted whether studies used a global common data model (CDM) such as those from OMOP (Observational Medical Outcomes Partnership)<sup>12 13</sup> or Sentinel,<sup>14 15</sup> and whether they were part of a wider programme or initiative for developing database networks and methods for combining results—such as IMI-PROTECT (Innovative Medicines Initiative Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium),<sup>16 17</sup> EU-ADR (European Union Adverse Drug Reaction database network)<sup>18</sup> or ARITMO (Arrhythmogenic Potential of Medicines project).<sup>19 20</sup>

The focus of the review was on describing the range of multi-database studies and methods for combining primary care EHR data, rather than evaluating evidence of effectiveness of specific interventions. Given this, and in the absence of consensus or validated reporting guidelines for multi-database studies, no formal assessment of risk of bias or study quality was attempted.

The study protocol, including the final Medline search strategy and details of data items extracted, is provided in online supplemental file 1.

### Patient and public involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

## RESULTS

The Medline and Embase searches returned 6049 results, and a further 5 were identified by hand searches. After initial screening of abstracts, 138 papers were selected for full text review, and 109 were included in the final review (figure 1). Summary information on the included studies is provided in online supplemental table S1.

Included studies used data from 38 different primary care EHR databases. Most studies (98, 89%) used 2 or 3 primary care EHR databases, and 43 studies (39%) also included 1 or more non-primary care EHR database. All but 3 studies used exclusively European primary care data, and 35 (32%) used data from a single country. Details of the primary care EHR databases used in included studies are summarised in online supplemental table S2.

The annual number of published studies increased over time (online supplemental figure S1), with fewer than 10 studies per year between 2003 and 2013, while a peak in 2016 (25 studies) included 10 studies published

in a special supplement on the IMI-PROTECT research programme.<sup>16 17</sup>

General characteristics of included studies are given in table 1. More than half (62 studies, 57%) were classified as analytical. Most studies (76, 70%) examined safety, effectiveness or utilisation of specific drugs accounted for, while 21% (23 studies) were disease epidemiology or risk prediction studies with no specific focus on pharmacological therapies.

Cohort studies were the most common study design (72 studies, 66%), and the majority of these were descriptive. Six studies included more than one study design.


The most common approach for data management and analysis was a fully centralised model (44 studies, 40%). A fully distributed model was used in 23 studies (21%), including 15 studies conducted as part of the IMI-PROTECT programme.<sup>16 21</sup> A partially distributed approach was used in 20 studies (18%), including 9 studies from the EU-ADR programme<sup>18</sup> and 5 from the ARITMO project.<sup>19 20</sup> No studies reported using a CDM.

Methodological aspects of the 62 analytical studies are summarised in table 2. All 23 case-control studies employed individual matching, and used conditional logistic regression to estimate adjusted ORs, but for cohort studies a range of statistical approaches was used.

In 22 analytical studies (35%), data were not combined, and all results were presented separately for each database—usually in order to describe and assess the consistency of findings in different populations or settings, using a common study protocol and analysis approach. In the remaining five studies, risk prediction models were developed in one primary care EHR database, and validated using a second primary care EHR database from the same country (the UK).<sup>22–26</sup>

In 40 analytical studies (65%), including the majority (20/23) of case-control studies, and half (18/34) of cohort studies, some form of pooled analysis or meta-analysis was undertaken. A one-stage meta-analysis of pooled IPD or partially aggregated data was undertaken in 29 studies (47%). In 19 of these studies, no assessment or discussion of between-database heterogeneity was provided, and only 4 studies reported any form of analytical adjustment for the clustered nature of the pooled data—in each case by including database as a covariate in a multiple regression model, with one study also including interaction terms between database and covariates.<sup>27</sup> Two-stage meta-analysis of database-specific effect estimates was used in 21 studies (34%), of which 14 presented some discussion or formal assessment of heterogeneity. The choice of FE or RE models was not clearly justified in most studies, though in four cases model choice was based on formal tests of heterogeneity (results not shown).

In 41 analytical studies (66%), separate effect estimates were reported for each database. Between database heterogeneity was formally assessed (most commonly using the  $I^2$  statistic) in 17 studies (27%) and was discussed but not formally assessed in a further 6 studies (10%). In 17 studies (27%)—all of which used a one-stage approach—results



**Figure 1** Selection and inclusion of studies for systematic review (adapted from Moher *et al*<sup>70</sup>).

were presented for the combined dataset only. Only 2 of these 17 studies additionally included a two-stage meta-analysis and reported heterogeneity statistics.

Ten studies reported comparable results (in the main paper or in supplementary materials) using two or more analytic approaches, such as both one-stage and two-stage meta-analysis (nine studies), or two-stage analysis with both FE and RE models (one study), summarised in [figure 2](#). In most cases one-stage and two-stage meta-analysis gave very similar results. CIs from RE meta-analysis were in almost every case wider than the corresponding FE or one-stage model estimates. In one study (review database id: 117), point estimates from one-stage and two-stage meta-analyses differed appreciably, and RE model CIs were wider, partly because some databases with very small numbers of cases were excluded.<sup>28</sup> In one self-controlled case series study examining risk of upper gastrointestinal bleeding with different drugs alone and in combination, the point estimates from one-stage model (ignoring clustering) and two-stage RE effects models were very

different (review database id: 113a-d), and CIs from the two-stage models were much wider.<sup>29</sup>

## DISCUSSION

This systematic review identified 109 multi-database studies, which used data from 2 or more primary care EHR data sources, the great majority of which were from European countries. Just under half were descriptive studies undertaken either to compare patterns and trends in different populations or settings, or to assess comparability of different EHR databases from similar populations. In these descriptive studies, and in a third of analytical studies, there was no attempt to combine results from the different databases. Where data was combined, a one-stage meta-analysis of pooled IPD was used more often than two-stage meta-analysis of database-specific results. Reporting of statistical methods for one-stage analyses in particular was suboptimal: in all but four such

**Table 1** General characteristics of included studies, including objective, rationale and study design

	Study type			All	%
	Analytical	Descriptive	Other*		
<b>All Studies</b>	62	45	2	109	
Study objective					
Drug safety	37	5		42	38.5
Drug utilisation	3	24	1	28	25.7
Disease epidemiology	7	9		16	14.7
Disease risk prediction	5	2		7	6.4
Drug comparative effectiveness	6			6	5.5
Methodology/data quality	2	3	1	6	5.5
Health services research	2	2		4	3.7
Main rationale for using multiple data sources (stated or inferred)					
Describe trends and variation between countries or settings	2	28		30	27.5
Increase study power	24	2		26	23.9
Examine consistency of findings in different settings (using a standardised approach or common study protocol)	19	3		22	20.2
Compare availability/quality of data in each source	2	7	2	11	10.1
Validation of findings in a second data source	5	3		8	7.3
Not clearly stated	10	2		12	11.0
Databases per study: primary care EHR only					
Mean	2.4	2.9	2.5	2.6	
Median (range)	2 (2–4)	3 (2–5)	2.5 (2–3)	2 (2–5)	
Databases per study: all types					
Mean	3.1	4.3	5.0	3.7	
Median (range)	2 (2–8)	4 (2–8)	5 (2–8)	3 (2–8)	
Database setting					
Single country	25	9	1	35	31.8
Multi-country	37	36	1	75	68.2
Study design†					
Cohort study	33	38	1	72	66.1
Case–control study	23	0	0	23	21.1
Cross-sectional	1	6	1	8	7.3
Self-controlled designs	7	0	0	7	6.4
Other	0	1	1	2	1.8
Interrupted time series	1	0	0	1	0.9
Data management and analysis model (stated or inferred)					
Centralised management and analysis: raw data shared	32	11	1	44	40.4
Distributed management and analysis: aggregated results shared	11	12		23	21.1
Distributed management+centralised analysis: patient level or partially aggregated data shared	11	8	1	20	18.3
Not described	8	14		22	20.2
Study drug (ATC chapter)					
Nervous system	11	8		19	17.4
Respiratory system	9	5		14	12.8
Musculoskeletal system	9	3		12	11.0
Multiple categories	7	4		11	10.1

Continued



Table 1 Continued

	Study type			All	%
	Analytical	Descriptive	Other*		
Alimentary tract and metabolism	6	3	1	10	9.2
Antiinfectives for systemic use	4	4		8	7.3
Cardiovascular system	2	2		4	3.7
Genito urinary system and sex hormonesc	2	1		3	2.8
Blood and blood forming organs		2		2	1.8
Dermatologicals		1		1	0.9
N/A	12	12	1	25	22.9
Study condition (ICD-10 chapter)					
Diseases of the circulatory system (I00–I99)	15	4		19	17.4
Diseases of the respiratory system (J00–J99)	11	4		15	13.8
Diseases of the digestive system (K00–K95)	9	4		13	11.9
Multiple categories	3	7		10	9.2
Endocrine, nutritional and metabolic diseases (E00–E89)	4	3	2	9	8.3
Injury, poisoning and certain other consequences of external causes (S00–T88)	6	1		7	6.4
Neoplasms (C00–D49)	5	1		6	5.5
Diseases of the musculoskeletal system and connective tissue (M00–M99)	4	1		5	4.6
Diseases of the nervous system (G00–G99)	2	3		5	4.6
Pregnancy, childbirth and the puerperium (O00–O9A)	1	3		4	3.7
Certain infectious and parasitic diseases (A00–B99)		2		2	1.8
Diseases of the skin and subcutaneous tissue (L00–L99)		2		2	1.8
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50–D89)		1		1	0.9
Diseases of the genitourinary system (N00–N99)	1			1	0.9
Health status, including morbidity and/or mortality	1			1	0.9
Mental, behavioural and neurodevelopmental disorders (F01–F99)		1		1	0.9
N/A		8		8	7.3

\*Other study type category included: case definition validation by chart review (one study) and prescribing data quality assessment (one study).

†Six studies included multiple designs and, therefore, included each relevant category: case-control and cohort [three studies]; case-crossover and self-controlled case series (SCCS) (two studies) and cohort study and SCCS (one study).

ATC, Anatomical Therapeutic Chemical Classification; EHR, electronic health record; ICD-10, International Classification of Diseases 10th Revision.

studies, adjustment for clustering or effect heterogeneity was either not explored or not reported.

Whether and how to combine data is a key consideration in multi-database studies, and our results are consistent with a previous systematic review which found that 16 out of 22 multi-database pharmacoepidemiology studies used a one-stage approach to combine the data.<sup>4</sup>

One-stage meta-analysis approaches have gained popularity over the past two decades as a technique for combining individual participant' data from randomised controlled trials and other clinical studies that collect primary data, identified in systematic reviews.<sup>30–32</sup> One-stage meta-analysis has a number of advantages relevant to multi-database studies, which combine IPD from

secondary data sources.<sup>33</sup> First, it ensures standardisation of the statistical analysis across all data sources. Second, it provides maximum flexibility to explore dose-response patterns, subgroup analyses and effect modification, all of which may help to account for heterogeneity between data sources. Third, a one-stage approach can incorporate information from smaller databases with sparse data, even where the database-specific effect cannot be reliably estimated due to zero cell counts.<sup>28 34 35</sup> However, one-stage meta-analysis of IPD should properly account for the clustered nature of the data from contributing databases,<sup>27 36–39</sup> since not doing so may introduce bias, especially if there is between-study heterogeneity in effect estimates. The results of this review suggest that clustering

**Table 2** Methodological aspects of analytical studies (N=62)

Characteristic	Study design*				All	%
	Case-control studies	Cohort studies	Self-controlled studies	Other†		
All studies	23	34	7	2	62	
Statistical methods‡						
Logistic regression	23	8	2	1	34	54.8
Poisson regression		6	6		12	19.4
Cox regression		18			18	29.0
Other§		9	1	1	11	17.7
Confounder control‡						
Multiple regression or Mantel Haenszel test	23	32		2	55	88.7
Matching	23	9		1	29	46.8
Case only/self-controlled design			7		7	11.3
Propensity scores		3			3	4.8
Instrumental variables		2			2	3.2
None		1			1	1.6
Database comparisons/heterogeneity assessment‡						
Participant characteristics presented for each database	17	24	4	2	45	72.6
Effect estimates presented for each database	18	19	5	2	41	66.1
Formal test of effect heterogeneity	10	4	3		17	27.4
I <sup>2</sup>	6	3	3		12	19.4
Cochran's Q	2	1			3	4.8
Other or not specified	3				3	4.8
No database comparisons (combined effect estimates only)	5	11	2		17	27.4
Method for combining data or results‡						
Data not combined	3	16	3	2	22	35.5
Meta-analysis (two-stage)	15	4	3		21	33.9
Random effects	10	2	2		13	21.0
Fixed effects	7	3	2		13	21.0
Method not specified		1			1	1.6
Pooled analysis (one-stage)	12	15	3		29	46.8
Multiple: one-stage and two-stage	7	1	2		10	16.1

\*Six studies contributed to multiple categories because they included multiple designs: case-control and cohort (three studies); case-crossover and self-controlled case series (SCCS) (two studies) and cohort study and SCCS (one study).


†One cross-sectional and one interrupted time series.

‡A single study could be included in more than one category.

§Other statistical methods included: negative binomial regression (two studies); Mantel-Haenszel test (two studies); two-stage instrumental variable (IV) models (two studies); 'data-mining methods' (two studies); generalised linear models (one study) and univariate tests (one study).

is largely ignored in multi-database studies using primary care EHR data, and this is consistent with findings from other reviews of one-stage meta-analysis in systematic reviews,<sup>30 31</sup> and in multi-database pharmacoepidemiology studies.<sup>4 27</sup> Barriers to the adoption of methods that properly account for clustering may include the perceived statistical complexity, lack of options in commonly available statistical software or because they can be computationally intensive.<sup>27 40</sup>

A third of analytical studies in this review used a two-stage approach to combine database-specific effect estimates to produce a pooled estimate. This approach avoids the need to share potentially sensitive IPD and may, therefore, be the only available option in some instances. It can also take advantage of local expertise and knowledge of each database partner, including optimising the use of available covariate information to control for confounding. In addition, a two-stage meta-analysis is relatively straightforward



**Figure 2** Comparison of relative risk (RR) estimates reported in studies using two or more methods to combine data from multiple sources. [study] refers to the review database id number (see online supplemental table S1).

to implement and interpret. It is also possible to conduct pre-planned subgroup analyses, or examine dose–response effects using a two-stage approach, although sparse data may limit this, since databases with zero cell counts in one or both comparison groups will usually have to be excluded, unless some form of continuity correction is used, which can introduce bias.<sup>41</sup>

As for meta-analysis of randomised and prospective studies, a second key consideration for multi-database studies is how to assess and interpret results in the presence of heterogeneity. Limitations associated with using secondary data not collected for the specific study question impose an additional challenge in this context.<sup>1 2</sup> Several approaches for harmonising analyses of multi-database studies have been used. These include development and adoption of consistent and validated case definitions, use of common protocols and statistical analysis plans, and shared data management and analysis routines, all aiming to reduce external sources of variability in results from different databases.<sup>10 11 16 17 19</sup> Nevertheless, in studies incorporating data from different countries with different population characteristics and healthcare systems, these factors may contribute to real differences in the effect estimates. Even within a single country, different primary care EHR software systems are used, which may introduce heterogeneity in the extracted data.<sup>42–47</sup> With one-stage analysis, both clustering and heterogeneity can be naturally explored in hierarchical models incorporating FE and/or RE, though as already noted the tendency has been to ignore this issue in multi-database studies. For two-stage meta-analysis, we found that FE and RE models were used equally frequently and

model choice, where discussed at all, was generally related to the presence or absence of heterogeneity. Relatively few studies justified the choice based on some formal measure or test for heterogeneity, a practice which has been criticised because such tests often have low power. This is a problem especially when the number of studies or databases is small,<sup>48</sup> and can result in an FE model being used even though heterogeneity is present and an RE model may have been more appropriate.<sup>49</sup> Simulation studies have shown that the  $I^2$  statistic can also be unreliable, either underestimating or overestimating heterogeneity in certain circumstances, particularly when the number of studies or databases is small.<sup>50 51</sup>

Several countries (Italy, Netherlands, Spain and the UK) now have two or more primary care EHR databases, and combining sources from the same country may reduce heterogeneity. In such cases, an FE model may be appropriate, especially where supporting analyses demonstrate substantial similarities in patient characteristics. Of eight single-country studies identified in this review and using two-stage meta-analysis, all eight used FE models<sup>52–59</sup>—despite evidence of substantial heterogeneity in some cases, although two studies did also use RE models for some analyses.<sup>52 53</sup>

When combining primary care EHR data from different countries or settings, an RE model might seem most appropriate, since these incorporate uncertainty in effect size when heterogeneity is present, yet reduce to an FE model if there is no heterogeneity.<sup>48</sup> However, when the number of estimates being combined is very small (<5) and heterogeneity is present—a common scenario in multi-database studies—conventional RE models may



**Table 3** Recommendations

Recommendation	Rationale
Studies should report clearly on all aspects of study design and conduct which impact on harmonisation of analyses across data sources.	Allows assessment of the relative importance of heterogeneity induced by data management and analysis decisions vs heterogeneity inherent in the data.
Participant characteristics and effect estimates (where applicable) should be reported for each data source.	Assessment of heterogeneity is essential for interpretation, but formal methods for quantifying heterogeneity are inefficient and possibly biased in multi-database settings.
Where one-stage methods are used, studies should report whether and how analyses accounted for clustering and between database heterogeneity.	Interpretation requires understanding of extent to which heterogeneity might influence study results.
Where two-stage meta-analysis is used, studies should provide a clear rationale for choice of fixed effect (FE), random effects (RE) or other model.	Interpretation requires understanding of extent to which heterogeneity might influence study results.
Sensitivity analyses should include alternative methods for combining data.	Comparing the results of one-stage vs two-stage analyses, or FE vs RE models, provides information about potential impact of modelling assumptions.
Further research is needed to compare performance of one-stage and two-stage approaches for multi-database studies.	Relatively few studies have specifically addressed meta-analysis for multi-database studies.

perform poorly. Simulation studies show that they can produce CIs which are too narrow, thereby increasing type one error rates.<sup>60–63</sup> A number of alternatives to conventional RE models have been proposed which partially address these limitations in some circumstances<sup>60 63–66</sup>; nevertheless, several authors have urged caution when interpreting results from meta-analysis of very few heterogeneous studies.<sup>60 63 66</sup> For multi-database studies, it may, therefore, be helpful to present estimates for both FE and RE models—or other alternative models, but always along with the results from individual databases.

Despite the differences outlined above, where studies combined data using more than one method, they produced similar estimates in most cases. However, in at least one study, one-stage and two-stage methods yielded large differences in both the point estimates and their precision. This may in part be related to the substantial heterogeneity in the database-specific estimates (reported  $I^2$  between 86% and 98% for the estimates shown), but incomplete reporting of statistical methods limits further interpretation of these results. When the same modelling assumptions are used, one-stage and two-stage approaches are expected to give very similar results if the number of studies combined is relatively large.<sup>37</sup> However, few studies have systematically compared performance of one-stage and two-stage approaches for multi-database studies.<sup>27 67</sup>

### Limitations

The search strategy for this review included a list of named primary care EHR databases compiled from publicly available registers. This was to circumvent the poor sensitivity and specificity of conceptual searches based on MeSH terms, as reported in a previous review,<sup>4</sup> and confirmed in the current review. Our approach could have missed some eligible studies—if the abstract only mentioned primary care EHR data sources that were not in our list

or did not mention the use of health databases or related terms at all. We would also have missed non-English language and abstract-only publications. Nevertheless, we expect the number of missed studies to be small, and any such studies are unlikely to have differed systematically from the included studies in terms of key methodological aspects. A more recent inventory of EHR databases in Europe did not identify any additional primary care databases that were not included in our review.<sup>68</sup> A further limitation was that some subjective interpretation was occasionally necessary to classify aspects of certain studies—for example, the rationale for combining, or the methods for managing and analysing data. The use of two reviewers helped to achieve some consistency across the included studies.

In conclusion, we found a growing body of literature reporting on studies using two or more sources of primary care EHR data. These addressed a range of research questions, and in many cases the results were presented separately and not combined. When data was combined, a one-stage meta-analysis was preferred. One-stage methods offer advantages in terms of analytical flexibility but are only possible where data management and governance arrangements allow for sharing of IPD. However, in many studies using one-stage approaches, the clustered nature of data from multi-database studies was frequently ignored, with unknown impact for interpretation. Two-stage meta-analysis requires only sharing of aggregated results, but there are known limitations with current two-stage methods when the number of studies is small, especially when some heterogeneity is expected. Irrespective of whether a one-stage or two-stage approach is used, combined results should be accompanied by results from each data source separately. This information, together with clear and complete reporting on methods used to

standardise and analyse the data (including the rationale for these decisions), affords a more considered assessment of potential sources of heterogeneity and greatly aids interpretation of the overall results. These considerations are relevant more widely to multi-database studies irrespective of the types of EHR or administrative databases being used, particularly where the number of databases being combined is relatively small, as was generally the case in our sample. Further research is required to understand the impact of analysis methods and other design aspects on overall study quality, and the development of reporting guidelines for multi-database studies, or extension of the existing RECORD guidance,<sup>69</sup> might be an important first step. Table 3 summarises key recommendations arising from our review.

**Acknowledgements** We would like to thank Russell Burke (Information Services, London School of Hygiene and Tropical Medicine) for his advice on bibliographic search strategies.

**Contributors** I confirm that all authors made substantial contributions to the study (detailed below), agree with and give final approval of the content of the current version, and agree to be accountable for all aspects of the work and for resolving questions related to any part of the work if they arise. DD: study concept and design, including search strategy; data extraction proformas and study database design; screening of titles and abstracts, and data extraction; analysis; interpretation of results; and drafting of manuscript. MC: screening of titles and abstracts, and data extraction; interpretation of results; critical review of manuscript and approval of final version. RW, KB and ID: study concept and design, including search strategy; interpretation of results; critical review of manuscript and approval of final version. SE: interpretation of results, critical review of manuscript and approval of final version.

**Funding** This research was conducted as part of a postgraduate doctoral degree funded by the Clinical Practice Research Datalink. KB holds a Sir Henry Dale Fellowship funded by Wellcome and the Royal Society (grant number 107731/Z/15/Z).

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. The study database and data-extraction proformas are available on request from DD.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

#### ORCID iDs

Daniel Dedman <http://orcid.org/0000-0002-3699-5391>

Melissa Cabecinha <http://orcid.org/0000-0001-6869-4692>

#### REFERENCES

- 1 Strom BL. Overview of automated databases in pharmacoepidemiology. In: *Textbook of pharmacoepidemiology*. Chichester, UK: John Wiley & Sons Ltd, 2013: 118–22.
- 2 Hall GC, Sauer B, Bourke A, et al. Guidelines for good database selection and use in pharmacoepidemiology research. *Pharmacoepidemiol Drug Saf* 2012;21:1–10.
- 3 Devoe JE, Gold R, McIntire P, et al. Electronic health records vs Medicaid claims: completeness of diabetes preventive care data in community health centers. *Ann Fam Med* 2011;9:351–8.
- 4 Bazelier MT, Eriksson I, de Vries F, et al. Data management and data analysis techniques in pharmacoepidemiological studies using a pre-planned multi-database approach: a systematic literature review. *Pharmacoepidemiol Drug Saf* 2015;24:897–905.
- 5 Häyriinen K, Saranto K, Nykänen P. Definition, structure, content, use and impacts of electronic health records: a review of the research literature. *Int J Med Inform* 2008;77:291–304.
- 6 ENCePP. ENCePP resource database. Available: <http://www.encepp.eu/encepp/resourcesDatabase.jsp> [Accessed 18 Jan 2018].
- 7 B.R.I.D.G.E.-TO-DATA. DGI, LLC. Available: <https://www.bridgetodata.org/> [Accessed 23 Jan 2018].
- 8 Gentil M-L, Cuggia M, Fiquet L, et al. Factors influencing the development of primary care data collection projects from electronic health records: a systematic review of the literature. *BMC Med Inform Decis Mak* 2017;17:139.
- 9 Brown JS, Holmes JH, Shah K, et al. Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. *Med Care* 2010;48:S45–51.
- 10 Gini R, Schuemie M, Brown J, et al. Data extraction and management in networks of observational health care databases for scientific research: a comparison of EU-ADR, OMOP, Mini-Sentinel and MATRICE strategies. *EGEMS* 2016;4:2.
- 11 EC-C L, Stang P, Yang Y-HK, et al. International Multi-database pharmacoepidemiology: potentials and pitfalls. *Curr Epidemiol Reports* 2015;2:229–38.
- 12 Schuemie MJ, Gini R, Coloma PM, et al. Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases. *Drug Saf* 2013;36(Suppl 1):159–69.
- 13 Overhage JM, Ryan PB, Reich CG, et al. Validation of a common data model for active safety surveillance research. *J Am Med Inform Assoc* 2012;19:54–60.
- 14 Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. *Arch Intern Med* 2012;172:1582–9.
- 15 Platt R, Carnahan RM, Brown JS, et al. The U.S. food and drug administration's Mini-Sentinel program: status and direction. *Pharmacoepidemiol Drug Saf* 2012;21(Suppl 1):1–8.
- 16 Klungel OH, Kurz X, de Groot MCH, et al. Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. *Pharmacoepidemiol Drug Saf* 2016;25(Suppl 1):156–65.
- 17 Reynolds RF, Kurz X, de Groot MCH, et al. The IMI PROTECT project: purpose, organizational structure, and procedures. *Pharmacoepidemiol Drug Saf* 2016;25(Suppl 1):5–10.
- 18 Coloma PM, Schuemie MJ, Trifiro G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR project. *Pharmacoepidemiol Drug Saf* 2011;20:1–11.
- 19 Trifiro G, Coloma PM, Rijnbeek PR, et al. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? *J Intern Med* 2014;275:551–61.
- 20 Mor A, Frøsvlev T, Thomsen RW, et al. Antibiotic use varies substantially among adults: a cross-national study from five European countries in the ARITMO project. *Infection* 2015;43:453–72.
- 21 Abbing-Karahagopian V, Kurz X, de Vries F, et al. Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project. *Curr Clin Pharmacol* 2014;9:130–8.
- 22 Hippisley-Cox J, Coupland C. Individualising the risks of statins in men and women in England and Wales: population-based cohort study. *Heart* 2010;96:939–47.
- 23 Hippisley-Cox J, Coupland C. Development and validation of risk prediction equations to estimate future risk of blindness and lower limb amputation in patients with diabetes: cohort study. *BMJ* 2015;351:h5441.
- 24 Clegg A, Bates C, Young J, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. *Age Ageing* 2016;45:353–60.
- 25 Hippisley-Cox J, Coupland C. Predicting the risk of chronic kidney disease in men and women in England and Wales: prospective derivation and external validation of the QKidney scores. *BMC Fam Pract* 2010;11:49.
- 26 Hippisley-Cox J, Coupland C. Development and validation of risk prediction equations to estimate future risk of heart failure in patients with diabetes: a prospective cohort study. *BMJ Open* 2015;5:e008503.
- 27 La Gamba F, Corrao G, Romio S, et al. Combining evidence from multiple electronic health care databases: performances of one-

- stage and two-stage meta-analysis in matched case-control studies. *Pharmacoepidemiol Drug Saf* 2017;26:1213–9.
- 28 Trifiro G, de Ridder M, Sultana J, *et al.* Use of azithromycin and risk of ventricular arrhythmia. *CMAJ* 2017;189:E560–8.
  - 29 Masclee GMC, Valkhoff VE, Coloma PM, *et al.* Risk of upper gastrointestinal bleeding from different drug combinations. *Gastroenterology* 2014;147:784–92.
  - 30 Simmonds M, Stewart G, Stewart L. A decade of individual participant data meta-analyses: a review of current practice. *Contemp Clin Trials* 2015;45:76–83.
  - 31 Simmonds MC, Higgins JPT, Stewart LA, *et al.* Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. *Clin Trials* 2005;2:209–17.
  - 32 Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. *BMJ* 2010;340:c221.
  - 33 Thomas D, Radji S, Benedetti A. Systematic review of methods for individual patient data meta-analysis with binary outcomes. *BMC Med Res Methodol* 2014;14:79.
  - 34 Mokhles MM, Trifiro G, Dieleman JP, *et al.* The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease. *Pharmacol Res* 2012;65:358–64.
  - 35 Poluzzi E, Diemberger I, De Ridder M, *et al.* Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project. *Eur J Clin Pharmacol* 2017;73:1499–510.
  - 36 Austin PC, Merlo J. Intermediate and advanced topics in multilevel logistic regression analysis. *Stat Med* 2017;36:3257–77.
  - 37 Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. *Stat Med* 2017;36:855–75.
  - 38 Debray TPA, Moons KGM, van Valkenhoef G, *et al.* Get real in individual participant data (IPD) meta-analysis: a review of the methodology. *Res Synth Methods* 2015;6:293–309.
  - 39 Debray TPA, Moons KGM, Abo-Zaid GMA, *et al.* Individual participant data meta-analysis for a binary outcome: one-stage or two-stage? *PLoS One* 2013;8:e60650.
  - 40 Stewart GB, Altman DG, Askie LM, *et al.* Statistical analysis of individual participant data meta-analyses: a comparison of methods and recommendations for practice. *PLoS One* 2012;7:e46042.
  - 41 Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Stat Med* 2004;23:1351–75.
  - 42 Kumarapeli P, de Lusignan S. Using the computer in the clinical consultation; setting the stage, reviewing, recording, and taking actions: multi-channel video study. *J Am Med Inform Assoc* 2013;20:e67–75.
  - 43 De Clercq E, Van Casteren V, Jonckheer P, *et al.* Electronic patient record data as proxy of GPs' thoughts. *Stud Health Technol Inform* 2008;141:103–10.
  - 44 Tai TW, Anandarajah S, Dhoul N, *et al.* Variation in clinical coding Lists in UK general practice: a barrier to consistent data entry? *Inform Prim Care* 2007;15:143–50.
  - 45 De Wilde S, Carey IM, Bremner SA, *et al.* A comparison of the recording of 30 common childhood conditions in the Doctor's Independent Network and General Practice Research Databases. *Heal Stat Q* 2004;21–31.
  - 46 Sollie A, Roskam J, Sijmons RH, *et al.* Do GPs know their patients with cancer? Assessing the quality of cancer registration in Dutch primary care: a cross-sectional validation study. *BMJ Open* 2016;6:e012669.
  - 47 Carey IM, Cook DG, De Wilde S, *et al.* Implications of the problem orientated medical record (POMR) for research using electronic GP databases: a comparison of the doctors independent network database (DIN) and the general practice research database (GPRD). *BMC Fam Pract* 2003;4:14.
  - 48 Borenstein M, Hedges LV, Higgins JPT, *et al.* A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res Synth Methods* 2010;1:97–111.
  - 49 Kontopantelis E, Springate DA, Reeves D. A Re-analysis of the Cochrane library data: the dangers of unobserved heterogeneity in meta-analyses. *PLoS One* 2013;8:e69930.
  - 50 Thorlund K, Imberger G, Johnston BC, *et al.* Evolution of heterogeneity (I<sup>2</sup>) estimates and their 95% confidence intervals in large meta-analyses. *PLoS One* 2012;7:e39471.
  - 51 von Hippel PT. The heterogeneity statistic (I<sup>2</sup>) can be biased in small meta-analyses. *BMC Med Res Methodol* 2015;15:35.
  - 52 Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. *BMJ* 2015;350:h2135.
  - 53 Thomas SL, Minassian C, Ganesan V, *et al.* Chickenpox and risk of stroke: a self-controlled case series analysis. *Clin Infect Dis* 2014;58:61–8.
  - 54 Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case-control studies using two primary-care databases. *Br J Cancer* 2013;109:795–806.
  - 55 Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data. *BMJ* 2013;346:f114.
  - 56 Bremner SA, Carey IM, DeWilde S, *et al.* Infections presenting for clinical care in early life and later risk of hay fever in two UK birth cohorts. *Allergy* 2008;63:274–83.
  - 57 Bremner SA, Carey IM, DeWilde S, *et al.* Early-life exposure to antibacterials and the subsequent development of hayfever in childhood in the UK: case-control studies using the general practice research database and the doctors' independent network. *Clin Exp Allergy* 2003;33:1518–25.
  - 58 Bremner SA, Carey IM, DeWilde S, *et al.* Timing of routine immunisations and subsequent hay fever risk. *Arch Dis Child* 2005;90:567–73.
  - 59 Bremner SA, Carey IM, DeWilde S, *et al.* Vaccinations, infections and antibacterials in the first grass pollen season of life and risk of later hayfever. *Clin Exp Allergy* 2007;37:512–7.
  - 60 Gonnermann A, Framke T, Großhennig A, *et al.* No solution yet for combining two independent studies in the presence of heterogeneity. *Stat Med* 2015;34:2476–80.
  - 61 Röver C, Knapp G, Friede T. Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies. *BMC Med Res Methodol* 2015;15:99.
  - 62 Int'Hout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. *BMC Med Res Methodol* 2014;14:25.
  - 63 Friede T, Röver C, Wandel S, *et al.* Meta-analysis of two studies in the presence of heterogeneity with applications in rare diseases. *Biom J* 2017;59:658–71.
  - 64 Doi SAR, Barendregt JJ, Khan S, *et al.* Advances in the meta-analysis of heterogeneous clinical trials I: the inverse variance heterogeneity model. *Contemp Clin Trials* 2015;45:130–8.
  - 65 Stanley TD, Doucouliagos H. Neither fixed nor random: weighted least squares meta-regression. *Res Synth Methods* 2017;8:19–42.
  - 66 Seide SE, Röver C, Friede T. Likelihood-based random-effects meta-analysis with few studies: empirical and simulation studies. *BMC Med Res Methodol* 2019;19:16.
  - 67 Selmer R, Haglund B, Furu K, *et al.* Individual-based versus aggregate meta-analysis in multi-database studies of pregnancy outcomes: the Nordic example of selective serotonin reuptake inhibitors and venlafaxine in pregnancy. *Pharmacoepidemiol Drug Saf* 2016;25:1160–9.
  - 68 Pacurariu A, Plueschke K, McGettigan P, *et al.* Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation. *BMJ Open* 2018;8:e023090.
  - 69 Benchimol EI, Smeeth L, Guttman A, *et al.* The reporting of studies conducted using observational Routinely-collected health data (record) statement. *PLoS Med* 2015;12:e1001885.
  - 70 Moher D, Liberati A, Tetzlaff J, *et al.* Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.

# Multidatabase Systematic Review: Supplementary Appendix

Appendix S1: Review Protocol: Approaches for combining primary care EHR data from multiple sources: a systematic review of observational studies

# Appendix S1: Review Protocol: Approaches for combining primary care EHR data from multiple sources: a systematic review of observational studies

## Contents

1	Introduction.....	2
2	Rationale and scope .....	2
2.1	Objectives.....	2
3	Methods.....	2
3.1	Eligibility Criteria .....	2
3.2	Information sources .....	3
3.3	Search strategy.....	3
3.3.1	Test sets.....	3
3.3.2	Conceptual searches.....	3
3.3.3	Search of named databases and common terms .....	4
3.4	Study records .....	4
3.4.1	Data Management .....	4
3.4.2	Selection process .....	4
3.4.3	Data extraction .....	5
4	Data synthesis .....	6
5	References .....	7
6	Appendices.....	8
6.1	Appendix 1: OVID Medline Search Strategy for Systematic Review.....	8
6.2	Appendix 2: Data extraction tables.....	10

## 1 Introduction

A recent systematic review evaluated methods for data management and analysis of multi-database studies in pharmacoepidemiology. The current study adopted a similar approach, but with a specific focus on studies combining primary care EHR databases, while expanding the scope to include all areas of observational epidemiology and healthcare database research.

## 2 Rationale and scope

The primary aim was to describe the full range of completed studies which brought together primary care electronic health record (EHR) data from two or more sources, and to generate a clear overview of methods used to manage, assess variability in, and analyse the data. The main motivation for the review was to inform a planned study of cancer risk in patients with Huntington's disease combining data from two UK primary care EHR databases.

The review specifically covered 'horizontal' combination of data from different sources, containing data from different sets of individuals (possibly after deduplication). Here the primary purpose of combining might be to increase the number of individuals available for analysis, or increase the range of population settings to which findings can be applied (i.e. increase external validity). The review did not include studies where data sources were only combined 'vertically' i.e. linkage studies whereby data on the same individuals was combined to provide richer (deeper) information about each study participant.

As the focus was on analysis of primary care EHR data, the review was restricted to studies using primary care EHR data from at least two sources. For the purpose of this review, primary care EHR data was defined as data collected by primary care clinicians and related staff for the purpose of diagnosis, treatment, management, and delivery of care of individual patients. It may include information collected or contributed by other care providers (1). It excludes data generated primarily for administrative purposes such as claims data.

The review was conducted following the PRISMA guidelines for reporting in systematic reviews (2,3) [<http://www.prisma-statement.org>].

### 2.1 Objectives

1. Identify studies which combined data from two or more sources of primary care EHR data.
2. Summarise key study characteristics, including the main reasons or motivations for combining data from different EHR databases
3. Describe the methods used to manage and analyse data including, where applicable, methods for combining data.
4. Describe the methods used to assess and report heterogeneity between primary care EHR data sources.
5. Describe and summarise any reported differences between different primary care EHR data sources.

Quality and completeness of reporting of methods was assessed using criteria adapted from the STROBE (4) and RECORD (5) guidelines. No formal assessment of quality in terms of risk of bias was attempted, either for individual studies, or for particular methodological approaches.

## 3 Methods

### 3.1 Eligibility Criteria

1. Peer reviewed, English language publication of an observational study.

2. Study participants selected from at least *two* different primary care EHR data sources.
3. Re-analyses of previously reported cohorts were included if they used substantially different methods.

There were no specific eligibility criteria relating to exposures, comparator groups, outcomes, or study design.

### 3.2 Information sources

The following databases were searched for eligible studies

1. Medline (OVID)
2. EMBASE (OVID)

### 3.3 Search strategy

The key challenges anticipated when searching for relevant studies were the lack of a specific MeSH concept for multi-database studies (6), and the lack of consensus on terminology for such studies in the published literature. This raised the possibility of having to hand search all database studies.

#### 3.3.1 Test sets

Given the challenges outlined above, the performance of different search strategies was evaluated for their ability to recall results from the following test references sets:

Test Set 1: 1673 publications using CPRD or GPRD databases were identified using keyword searches in Medline.

Test Set 2: an *ad hoc* sample of 14 records identified from a published systematic review of multi-database pharmacoepidemiology studies (6), plus a small number identified from non-systematic review of the literature. All of these studies used at least one primary care EHR data source.

#### 3.3.2 Conceptual searches

An initial search strategy was defined based on 3 concepts, identified using both MeSH terms and keywords, and the sensitivity of each concept was assessed against Test Sets 1 and 2 :

1. Database studies: this included MeSH terms and keyword searches for databases and related concepts such as Electronic Health Records, and Computerized Medical Records System. This concept was reasonably sensitive for recalling CPRD/GPRD studies (Test Set 1 sensitivity=  $1365/1673 = 0.82$ ), and all records in the sample of multi-database studies (Test Set 2 sensitivity  $14/14 = 1$ ). However it returned over 395 thousand results.
2. Primary care setting: a combined MeSH term and keyword search returned over 280 thousand records, but had very low sensitivity with both Test Set 1 ( $526/1673 = 0.31$ ), and only moderate sensitivity with Test Set 2 ( $10/14 = 0.71$ ).
3. (Observational) epidemiology studies: The InterTASC Information Specialists' Sub-Group Search Filter Resource (7) was accessed to identify potentially suitable and validated search filters. Waffenschmidt *et al* (8) reviewed search strategies to identify epidemiological studies, concluding that there was "no suitable approach to conducting *efficient* systematic searches for epidemiologic publications in bibliographic databases". One filter, from a systematic review of Hepatitis C prevalence in prisons by Larney *et al* (9), was found to be suitably sensitive, recalling almost 96% of their test set of 729 references. This filter had very high sensitivity for CPRD/GPRD studies in Test Set 1 ( $1593/1673 = 0.95$ ), and also recalled all records in Test Set 2 (sensitivity  $14/14 = 1$ ). However it returned over 6 million records.

A Medline search combining all 3 of the concepts above returned 14309 records and recalled only 10 of the 14 records in Test Set 2 (sensitivity 0.71), with the sensitivity being limited by the 'Primary Care' concept. However any attempt to broaden this concept to improve sensitivity would have increased the number of recalled records beyond what could be feasibly reviewed manually. For example, broadening the Primary Care concept to include 'population-based' studies, allowed recall of 12/14 records from Test Set 2, but increased the total number of records retrieved to 23656.

### 3.3.3 Search of named databases and common terms

Given the relatively poor performance of the conceptual searches, an alternative strategy was developed using a combination of named databases, and commonly used key words and phrases. Three sources were used to compile a list of candidate primary care EHR (or closely related) databases:

1. ENCePP Resources Database: the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) maintains a searchable database of research organisations, networks and data sources (10). Despite a strong European focus, the register is not restricted to European data sources. The database was searched to identify 20 registered data sources identified as a 'Routine primary care electronic patient registry'.
2. B.R.I.D.G.E. TO DATA®: a "non-profit online reference describing population healthcare databases for use in epidemiology and health outcomes research" (10). A search interface is provided as a subscription service, however a simple listing of 286 named database resources was downloaded (23 Jan 2018) and searched for candidate primary care databases.
3. A list of 41 databases or primary care research networks identified in a 2017 review by Gentil et al (11) which examined factors associated with successful implementation of initiatives to collect and curate collections of primary care electronic health record data.

Abstracts of published studies identified from the initial named database search were scanned for additional terms and phrases used to describe the primary care EHR data sources, and these were added to the final search. Finally, reference lists of papers selected for full review were searched for additional studies.

The full search strategy used to search the Medline database is included in Appendix I.

This search was able to recall 12/14 records in Test Set 2 (sensitivity = 0.86), and all records in Test Set 1 (by definition - since CPRD/GPRD were among the named databases included in the search).

## 3.4 Study records

### 3.4.1 Data Management

All search results were exported from OVID in batches, with copies of export files retained. The references were imported into Mendeley V1.1 (Mendeley, Elsevier, Amsterdam, NL). Details of studies selected for full review were exported into a Microsoft Access database, in which was used to record subsequent inclusion/exclusion decisions and data extraction.

### 3.4.2 Selection process

Initial screening of all selected titles and abstracts was undertaken by 1 reviewer (DD). A second reviewer (MC) screened a 20% random sample of all abstracts. Full text was reviewed in instances where it was not possible to assess eligibility from the title and abstract alone.

Full text was then obtained for all papers selected during the initial abstract screening, and read by two reviewers, who completed the eligibility assessment before and performing data extraction.



### 3.4.3 Data extraction

Each reviewer extracted standardised information via a data collection form into a review database (MS Access). The following information was collected:

Year of publication
Primary care EHR data source details: <ul style="list-style-type: none"> <li>• number of sources</li> <li>• name(s) of database</li> <li>• country</li> </ul>
Other (non-primary care EHR) data source details: <ul style="list-style-type: none"> <li>• number of sources</li> <li>• name(s) of database</li> <li>• type of database e.g. claims, disease registry</li> <li>• country</li> </ul>
Study type or broad objective e.g.: <ul style="list-style-type: none"> <li>• Descriptive e.g. drug utilisation, disease epidemiology</li> <li>• Comparative or hypothesis testing e.g. comparative treatment effectiveness, drug safety, disease epidemiology</li> <li>• Disease risk prediction</li> <li>• Methodology / data quality assessment</li> <li>• Health service research</li> </ul>
Study design e.g.: <ul style="list-style-type: none"> <li>• Cross sectional</li> <li>• Case-control</li> <li>• Cohort</li> <li>• Case-only designs</li> <li>• Time series</li> </ul>
Target population(s) for study:
Main exposure(s) if applicable e.g.: <ul style="list-style-type: none"> <li>• Drug treatment</li> <li>• Disease risk factor</li> <li>• Other</li> </ul>
Main outcome(s) if applicable e.g.: <ul style="list-style-type: none"> <li>• All cause mortality</li> <li>• Disease</li> <li>• Treatment patterns</li> <li>• Other</li> </ul>
Main analysis methods, including confounder control e.g.: <ul style="list-style-type: none"> <li>• descriptive using summary statistics</li> <li>• incidence or prevalence calculations</li> <li>• multiple regression modelling</li> </ul>
Motivation or rationale for using and/or combining data sources e.g.: <ul style="list-style-type: none"> <li>• increase study power</li> <li>• assess consistency of findings in multiple settings</li> <li>• international comparisons</li> </ul>
Assessment of heterogeneity of exposures, outcomes and effect estimates e.g.: <ul style="list-style-type: none"> <li>• descriptive only (no formal comparisons)</li> <li>• univariate comparisons</li> <li>• formal tests for heterogeneity (Q-test, I-test)</li> </ul>
Main approach for combining data sources e.g.: <ul style="list-style-type: none"> <li>• Data not combined: results presented separately for each source</li> <li>• Meta-analysis of aggregate results from each data source</li> </ul>

<ul style="list-style-type: none"><li>• Meta-analysis of semi-aggregated results from each data source</li><li>• Pooled analysis of individual patient data</li></ul>
Data management and analysis e.g.: <ul style="list-style-type: none"><li>• Data managed and analysed separately by each database partner</li><li>• Use of common protocol</li><li>• Use of common data model (study specific, or externally defined e.g. OMOP CDM)</li><li>• Use of common analysis programs</li><li>• Data management and analysis arrangements (distributed, central, hybrid)</li><li>• Data sharing model (individual, semi-aggregate, aggregate)</li></ul>

## 4 Data synthesis

Results will be summarised in tables which will describe .

- basic characteristics of included studies: study design, statistical method
- rationale for combining databases
- methods used to assess heterogeneity
- methods use for combining or synthesising results

Further narrative descriptions will focus on specific subgroups. For example analytical studies which combined two or more databases from the same country.

## 5 References

1. Häyrynen K, Saranto K, Nykänen P. Definition, structure, content, use and impacts of electronic health records: a review of the research literature. *Int J Med Inform* [Internet]. 2008 May;77(5):291–304. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17951106>
2. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. *PLoS Med* [Internet]. 2009 Jul 21;6(7):e1000100. Available from: <http://dx.plos.org/10.1371/journal.pmed.1000100>
3. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* [Internet]. 2009 Aug 18;151(4):264–9, W64. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19622511>
4. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* [Internet]. 2008 Apr;61(4):344–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18313558>
5. Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. *PLoS Med* [Internet]. 2015 Oct;12(10):e1001885. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26440803>
6. Bazelier MT, Eriksson I, de Vries F, Schmidt MK, Raitanen J, Haukka J, et al. Data management and data analysis techniques in pharmacoepidemiological studies using a pre-planned multi-database approach: a systematic literature review. *Pharmacoepidemiol Drug Saf* [Internet]. 2015 Sep [cited 2017 Feb 15];24(9):897–905. Available from: <http://doi.wiley.com/10.1002/pds.3828>
7. Glanville J, Lefebvre C, Wright K. ISSG Search Filter Resource [Internet] [Internet]. York (UK): The InterTASC Information Specialists' Sub-Group; 2008. 2008 [cited 2018 Mar 12]. Available from: <https://sites.google.com/a/york.ac.uk/issg-search-filters-resource/how-to-cite-this-site>
8. Waffenschmidt S, Hermanns T, Gerber-Grote A, Mostardt S. No suitable precise or optimized epidemiologic search filters were available for bibliographic databases. *J Clin Epidemiol* [Internet]. 2017 Feb 1 [cited 2017 Oct 17];82:112–8. Available from: <http://www.sciencedirect.com/science/article/pii/S0895435616303663>
9. Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais D Des, Hagan H, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis. *Hepatology* [Internet]. 2013 Oct [cited 2017 Oct 17];58(4):1215–24. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23504650>
10. ENCePP. ENCePP Resource Database [Internet]. [cited 2018 Jan 18]. Available from: <http://www.encepp.eu/encepp/resourcesDatabase.jsp>
11. Gentil M-L, Cuggia M, Fiquet L, Hagenbourger C, Le Berre T, Banâtre A, et al. Factors influencing the development of primary care data collection projects from electronic health records: a systematic review of the literature. *BMC Med Inform Decis Mak* [Internet]. 2017 Dec 25 [cited 2017 Oct 24];17(1):139. Available from: <http://bmcmmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-017-0538-x>

## 6 Appendices

### 6.1 Appendix I: OVID Medline Search Strategy for Systematic Review

Run on 16 Feb 2018 on Medline to Feb Week 2 2018

Item	Term
1	Lifelink.mp.
2	Disease Analyzer.mp.
3	(OsMed not dysplasia).mp.
4	EpiChron.mp.
5	(Integrated Primary Care Information or IPCI or Interdisciplinary Processing of Clinical Information).mp.
6	PHARMO.mp.
7	(Primary Care Clinical Informatics Unit or PCCIU).mp.
8	(BIFAP or Database for Pharmacoepidemiolog* Research in Primary Care or Base de datos para la Investigacion Farmacoepidemiologica en Atencion Primaria).mp.
9	(SIDIAP or Information System for the Development of Research in Primary Care or (Sistema and Desenvolupament and Atencio Primaria)).mp.
10	((LINH and database) or Netherlands Information Network of General Practice or Landelijk Informatie Netwerk Huisatzenzorg).mp.
11	(NIVEL adj3 database).mp.
12	(CPRD or Clinical Practice Research Data*).mp.
13	(GPRD or General Practice Research Data*).mp.
14	(OPCRD or Optimum Patient Care Research Data*).mp.
15	((THIN adj4 database) or Health Information Network or Health Improvement Network).mp.
16	(QResearch or Q Research).mp.
17	(ResearchOne or (Research One adj4 database*)).mp.
18	(DIN LINK or (DIN adj4 database*) or Doctors Independent Network).mp.
19	((SAIL adj4 Data*) or Secure Anon* Information Link*).mp.
20	(Arianna data* or (Caserta and database)).mp.
21	Pedianet.mp.
22	(Health Search and (Database or Dataset)).mp.
23	Longitudinal Patient Database.mp.
24	(mediplus and database).mp.
25	(centricity and (database* or EMR or electronic medical record*)).mp.
26	OCHIN.mp.
27	PHINEX.mp.
28	Regenstrief Medical Record.mp.
29	(Clalit and database).mp.
30	(Electronic Medical Record Administrative data Linked Database or EMRALD).mp.
31	(Intego or (database* and (general practice or primary care) and Belgi*)).mp.
32	Julius General Practi*.mp.
33	((primary care or primary health care or general practi* or family practi* or ambulatory care) adj4 database*).mp.
34	population database*.mp
35	(healthcare adj2 database*).mp
36	health care database*.mp
37	(electronic health* adj2 database*).mp

38	(population health* adj2 database*).mp
39	((EHR or electronic health record*) adj2 database*).mp
40	Or/1-39
41	limit 40 to (abstracts and english language and yr="2000 -Current")

## 6.2 Appendix 2: Data extraction tables

### Table name: StudyInfo1

Description: Basic publication details

Completed for: All studies selected at initial screening round

Name	Type	Size	Description
StudyID	Long Integer	4	UNIQID for study
Authors	Long Text	-	
Title	Long Text	-	
JName	Short Text	255	Name of journal
JVol	Short Text	255	Journal volume
JPage	Short Text	255	Journal pages
YearPub	Long Integer	4	Year of publication

### Table name: DataSource1

Description: Key information about each primary care EHR database

Completed for: Each primary care EHR database, plus partial details collected for other databases described in the included studies

Name	Type	Size	Description
DataSourceID	Long Integer	4	UNIQID for datasource
SourceName	Short Text	255	Full or official name of database
Shortname	Short Text	255	Short name for database
Aliases	Short Text	255	Other names used in published papers
IsEHR	Short Text	10	Is it a primary care EHR database
SourceType	Integer	2	What type of database (primary care EHR or some other type)
SourceCountry	Short Text	255	Country of database
ClinicalCoding	Short Text	255	Name of clinical coding scheme (if known)
DrugCoding	Short Text	255	Name of drug coding scheme (if known)
SourceInfo1	Long Text	-	Other relevant information about data source
SourceReference	Long Text	-	Key reference for data source

### Table name: Review1

Description: Summary of review process, including whether publication was selected for full review

Completed for: All studies selected at initial screening round

Name	Type	Size	Description
Review1ID	Long Integer	4	record identifier
StudyID	Long Integer	4	ID number of paper being reviewed
ReviewerID	Integer	2	Reviewer: DD or MC (or adjudicated)
IncExc	Integer	2	Inclusion / exclusion with reasons
IncExcComment 1	Long Text	-	Comment on decision to include or exclude
Review1Date	Date With Time	8	Date of completion of review

**Table name: Review2**

Description: Full details of study objectives, methods and relevant results

Completed for: All studies included after full paper review

Name	Type	Size	Description
Review2ID	Long Integer	4	record identifier
StudyID	Integer	2	Study ID (FK)
ReviewerID	Short Text	20	Reviewer: DD or MC (or Adjudicated)
Review2Status	Short Text	255	set to "in progress" once data entry is started; user specifies when completed
Review2Date	Date With Time	8	autoset when status is set to completed
Objective	Short Text	50	Short description of study objectives
OBjectiveText	Long Text	-	Further details of study objectives, including quoted text from publication if relevant
TargetPop	Short Text	255	Short description of the target population or patient group for the study
TargetPopText	Long Text	-	Further details of target population, including quoted text from publication if relevant
MainExposures	Short Text	255	Lookup: category for main exposure(s)
MainExposuresText	Long Text	-	Further details of main exposure(s), including quoted text from publication if relevant
MainOutcomes	Short Text	255	Lookup: category for main outcome(s)
MainOutcomesText	Long Text	-	Further details of main outcome(s), including quoted text from publication if relevant
StudyType	Short Text	255	Lookup: type of study e.g drug safety; disease epidemiology;
StudyTypeText	Long Text	-	Further details of study type, including quoted text from publication if relevant
StudyDesign	Short Text	255	Lookup: study design e.g. cohort, case control, etc
StudyDesignText	Long Text	-	Further details of study design, including quoted text from publication if relevant
MainRationale	Short Text	255	Lookup: main reason for combining data from multiple sources
MainRationaleText	Long Text	-	Further details of study rationale, including quoted text from publication if relevant
Stats1	Short Text	255	Lookup: main statistical method or model used
Stats1Text	Long Text	-	Further details of statistical method or model including quoted text from publication if relevant
ExposureTime	Short Text	255	Lookup: main method for modelling exposure
ConfounderControl	Short Text	255	Lookup: main method for confounder adjustment
HeterogeneityAssess	Short Text	255	Lookup: main method for assessing heterogeneity
CombineMethod	Short Text	255	Lookup: main method for combining results
CombineMethodText	Long Text	-	Further details of combination methods including quoted text from publication if relevant

CompareExposure	Short Text	255	Lookup: main method for comparing exposure variables in each data source
CompareOutcome	Short Text	255	Lookup: main method for comparing outcome variables in each data source
CompareOther	Short Text	255	Lookup: main method for comparing other variables in each data source
CompareText	Long Text	-	Further details of methods used to compare variables including quoted text from publication if relevant
DataManagement	Short Text	255	Lookup: how was data managed e.g. central vs multicentre etc
DataManageText	Long Text	-	Further details of data management approach including quoted text from publication if relevant
Programming	Short Text	255	Lookup: how was programming managed e.g. central vs multicentre etc
ProgrammingText	Long Text	-	Further details of programming approach including quoted text from publication if relevant



# Multidatabase Systematic Review: Supplementary Tables and Figures

Figure S1: Number of included studies by year of publication

Table S1: Summary details of 109 studies included in systematic review

Table S2: Summary details of primary care electronic health record (EHR) data sources used in studies included in systematic review

Figure S1: Number of included studies by year of publication




Table S1: Summary details of 109 studies included in systematic review.

Study ID <sup>a</sup>	Citation	Resource locator: [doi unless specified otherwise] <sup>b</sup>	Study topic	Study type	Study design <sup>c</sup>	Data combining	Primary care EHR data sources <sup>d</sup>	Other sources (if applicable)
1	Lum KJ, Newcomb CW, Roy JA, et al. Evaluation of methods to estimate missing days' supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). <i>Eur J Clin Pharmacol</i> 2017;73:115–23	10.1007/s00228-016-2148-4	Drug utilization	Other	Other	Data not combined	2: CPRD; THIN	
2	de Bie S, Kaguelidou F, Verhamme KMC, et al. Using Prescription Patterns in Primary Care to Derive New Quality Indicators for Childhood Community Antibiotic Prescribing. <i>Pediatr Infect Dis J</i> 2016;35:1317–23	10.1097/INF.0000000000001324	Drug utilization	Descriptive	Cohort	Data not combined	3: IPCI; Pedianet; THIN	
3	Masclée GMC, Coloma PM, Spaander MCW, et al. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based Case-control. <i>BMJ Open</i> 2015;5:e006640	10.1136/bmjopen-2014-006640	Drug safety	Analytical	Case-control	Pooled analysis: individual patient data	2: IPCI; THIN	
7	Laforest L, Licaj I, Devouassoux G, et al. Prescribed therapy for asthma: therapeutic ratios and outcomes. <i>BMC Fam Pract</i> 2015;16:49	10.1186/s12875-015-0265-2	Drug comparative effectiveness	Analytical	Cohort	Data not combined	2: LPD (France); THIN	
8	Afonso A, Schmiedl S, Becker C, et al. A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction. <i>Eur J Clin Pharmacol</i> 2016;72:1105–16	10.1007/s00228-016-2071-8	Drug safety	Analytical	Cohort	Data not combined	2: CPRD; NPCRD (Mondriaan)	1
9	Ali MS, Groenwold RHH, Belitser S V, et al. Methodological comparison of marginal structural model, time-varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture. <i>Pharmacoepidemiol Drug Saf</i> 2016;25 Suppl 1:114–21	10.1002/pds.3864	Drug safety	Analytical	Cohort	Data not combined	3: AHC (Mondriaan); BIFAP; NPCRD (Mondriaan)	
10	Bezemer ID, Verhamme KMC, Gini R, et al. Use of oral contraceptives in three European countries: a population-based multi-database study. <i>Eur J Contracept Reprod Health Care</i> 2016;21:81–7	10.3109/13625187.2015.1102220	Drug utilization	Descriptive	Cohort	Data not combined	3: HSD (Italy); IPCI; THIN	1
11	Brauer R, Douglas I, Garcia Rodriguez LA, et al. Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe. <i>Pharmacoepidemiol Drug Saf</i> 2016;25 Suppl 1:29–38	10.1002/pds.3861	Drug safety	Analytical	Multiple: case-control; cohort	Data not combined	2: BIFAP; CPRD	
12	Brauer R, Ruigómez A, Downey G, et al. Prevalence of antibiotic use: a comparison across various European health care data sources. <i>Pharmacoepidemiol Drug Saf</i> 2016;25 Suppl 1:11–20	10.1002/pds.3831	Drug utilization	Descriptive	Cross-sectional	Data not combined	5: AHC (Mondriaan); BIFAP; CPRD; NPCRD (Mondriaan); THIN	2
14	Castellsague J, Perez-Gutthann S, Calingaert B, et al. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. <i>Pharmacoepidemiol Drug Saf</i> 2017;26:615–24	10.1002/pds.4167	Drug utilization	Descriptive	Cohort	Data not combined	2: SIDIAP; THIN	3
15	Charlton RA, Pierini A, Klungsøyr K, et al. Asthma medication prescribing before, during and after pregnancy: a study in seven European regions. <i>BMJ Open</i> 2016;6:e009237	10.1136/bmjopen-2015-009237	Drug utilization	Descriptive	Cohort	Data not combined	2: CPRD; SAIL	5
16	Charlton R, Garne E, Wang H, et al. Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regions. <i>Pharmacoepidemiol Drug Saf</i> 2015;24:1144–54	10.1002/pds.3847	Drug utilization	Descriptive	Cohort	Data not combined	2: CPRD; SAIL	5
17	Chui CSL, Chan EW, Wong AYS, et al. Association between oral fluoroquinolones and seizures: A self-controlled case series study. <i>Neurology</i> 2016;86:1708–15	10.1212/WNL.0000000000002633	Drug safety	Analytical	SCCS	Meta-analysis: random effects	2: CDARS; CPRD	
18	Clegg A, Bates C, Young J, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. <i>Age Ageing</i> 2016;45:353–60	10.1093/ageing/afw039	Disease risk prediction	Analytical	Cohort	Data not combined	2: ResearchOne; THIN	
19	De Bortoli N, Ripellino C, Cataldo N, et al. Unspecified intestinal malabsorption in patients treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: a retrospective analysis in primary care settings. <i>Expert Opin Drug Saf</i> 2017;16:1221–5	10.1080/14740338.2017.1376647	Drug safety	Descriptive	Cohort	Pooled analysis: individual patient data	2: Disease Analyzer (Germany); HSD (Italy)	

Study ID <sup>a</sup>	Citation	Resource locator: [doi unless specified otherwise] <sup>b</sup>	Study topic	Study type	Study design <sup>c</sup>	Data combining	Primary care EHR data sources <sup>d</sup>	Other sources (if applicable)
20	de Groot MCH, Candore G, Uddin MJ, et al. Case-only designs for studying the association of antidepressants and hip or femur fracture. <i>Pharmacoepidemiol Drug Saf</i> 2016;25 Suppl 1:103–13	10.1002/pds.3850	Drug safety	Analytical	Multiple: CCX; SCCS	Data not combined	3: AHC (Mondriaan); NPCRD (Mondriaan); THIN	
24	Ferrajolo C, Verhamme KMC, Trifirò G, et al. Antibiotic-Induced Liver Injury in Paediatric Outpatients: A Case-control in Primary Care Databases. <i>Drug Saf</i> 2017;40:305–15	10.1007/s40264-016-0493-y	Drug safety	Analytical	Case-control	Pooled analysis: individual patient data	3: HSD (Italy); IPCI; Pédianet	
25	Gold R, Esterberg E, Hollombe C, et al. Low Back Imaging When Not Indicated: A Descriptive Cross-System Analysis. <i>Perm J</i> 2016;20:25–33	10.7812/TPP/15-081	Health services research	Analytical	Cohort	Pooled analysis: individual patient data	2: KP Clarity (Epic EHR); OCHIN Clarity (Epic EHR)	
26	Hippisley-Cox J, Coupland C. Development and validation of risk prediction equations to estimate future risk of blindness and lower limb amputation in patients with diabetes: Cohort. <i>BMJ</i> 2015;351:h5441	10.1136/bmj.h5441	Disease risk prediction	Analytical	Cohort	Data not combined	2: CPRD; QResearch	
27	Hippisley-Cox J, Coupland C. Development and validation of risk prediction equations to estimate future risk of heart failure in patients with diabetes: a prospective Cohort. <i>BMJ Open</i> 2015;5:e008503	10.1136/bmjopen-2015-008503	Disease risk prediction	Analytical	Cohort	Data not combined	2: CPRD; QResearch	
28	Israel E, Roche N, Martin RJ, et al. Increased Dose of Inhaled Corticosteroid versus Add-On Long-acting $\beta$ -Agonist for Step-Up Therapy in Asthma. <i>Ann Am Thorac Soc</i> 2015;12:798–806	10.1513/AnnalsATS.201412-580OC	Drug comparative effectiveness	Analytical	Cohort	Pooled analysis: individual patient data	2: CPRD; OPCR	
30	Levi M, Rosselli M, Simonetti M, et al. Epidemiology of iron deficiency anaemia in four European countries: a population-based study in primary care. <i>Eur J Haematol</i> 2016;97:583–93	10.1111/ejh.12776	Disease epidemiology	Descriptive	Cohort	Data not combined	4: HSD (Italy); LPD (Belgium); LPD (Germany); LPD (Spain)	
31	Levin D, Bell S, Sund R, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. <i>Diabetologia</i> 2015;58:493–504	10.1007/s00125-014-3456-9	Drug safety	Analytical	Cohort	Meta-analysis: fixed & random effects	2: CPRD; SIR	4
32	Murray CS, Thomas M, Richardson K, et al. Comparative Effectiveness of Step-up Therapies in Children with Asthma Prescribed Inhaled Corticosteroids: A Historical Cohort. <i>J allergy Clin Immunol Pract</i> 2017;5:1082-1090.e7	10.1016/j.jaip.2016.12.28	Drug comparative effectiveness	Analytical	Cohort	Pooled analysis: individual patient data	2: CPRD; OPCR	
33	Nyberg F, Home L, Morlock R, et al. Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis. <i>Adv Ther</i> 2016;33:1180–98	10.1007/s12325-016-0346-1	Disease epidemiology	Descriptive	Cohort	Data not combined	3: CPRD; Disease Analyzer (France); Disease Analyzer (Germany)	1
34	Oteri A, Mazzaglia G, Pecchioli S, et al. Prescribing pattern of antipsychotic drugs during the years 1996-2010: a population-based database study in Europe with a focus on torsadogenic drugs. <i>Br J Clin Pharmacol</i> 2016;82:487–97	10.1111/bcp.12955	Drug utilization	Descriptive	Cohort	Data not combined	3: HSD (Italy); IPCI; THIN	4
35	Petersen I, McCrea RL, Sammon CJ, et al. Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records. <i>Health Technol Assess</i> 2016;20:1–176	10.3310/hta20230	Drug safety	Analytical	Cohort	Pooled analysis: individual patient data	2: CPRD; THIN	
36	Petherick ES, Pickett KE, Cullum NA. Can different primary care databases produce comparable estimates of burden of disease: results of a study exploring venous leg ulceration. <i>Fam Pract</i> 2015;32:374–80	10.1093/fampra/cm013	Disease epidemiology	Descriptive	Cohort	Data not combined	2: CPRD; THIN	
37	Rathmann W, Czech M, Franek E, et al. Regional differences in insulin therapy regimens in five European countries. <i>Int J Clin Pharmacol Ther</i> 2017;55:403–8	10.5414/CP202906	Drug utilization	Descriptive	Cross-sectional	Data not combined	3: Disease Analyzer (France); Disease Analyzer (Germany); Disease Analyzer (UK)	2
38	Requena G, Huerta C, Gardarsdottir H, et al. Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): a methodological approach to assess consistencies across databases from the PROTECT-EU project. <i>Pharmacoepidemiol Drug Saf</i> 2016;25 Suppl 1:66–78	10.1002/pds.3816	Drug safety	Analytical	Multiple: case-control; cohort	Meta-analysis: random effects	3: BIFAP; CPRD; NPCRD (Mondriaan)	
39	Requena G, Logie J, Martin E, et al. Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines. <i>Pharmacoepidemiol Drug Saf</i> 2016;25 Suppl 1:79–87	10.1002/pds.3822	Drug safety	Analytical	Multiple: CCX;SCCS	Data not combined	2: BIFAP; CPRD	

Study ID <sup>a</sup>	Citation	Resource locator: [doi unless specified otherwise] <sup>b</sup>	Study topic	Study type	Study design <sup>c</sup>	Data combining	Primary care EHR data sources <sup>d</sup>	Other sources (if applicable)
40	Saine ME, Carbonari DM, Newcomb CW, et al. Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. <i>BMC Pharmacol Toxicol</i> 2015;16:8	10.1186/s40360-015-0007-z	Drug utilization	Analytical	Cross-sectional	Data not combined	2: CPRD; THIN	2
41	Souverein PC, Abbing-Karahagopian V, Martin E, et al. Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures. <i>Pharmacoepidemiol Drug Saf</i> 2016;25 Suppl 1:88–102	10.1002/pds.3862	Drug safety	Analytical	Multiple: case-control; cohort	Data not combined	4: AHC (Mondriaan); BIFAP; NPCRD (Mondriaan); THIN	
43	Sultana J, Fontana A, Giorgianni F, et al. The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study. <i>CNS Drugs</i> 2016;30:1097–109	10.1007/s40263-016-0366-z	Health services research	Analytical	Interrupted time series	Data not combined	2: HSD (Italy); THIN	
44	Turner SW, Richardson K, Burden A, et al. Initial step-up treatment changes in asthmatic children already prescribed inhaled corticosteroids: a historical Cohort. <i>NPJ Prim care Respir Med</i> 2015;25:15041	10.1038/npjpcrm.2015.41	Drug utilization	Descriptive	Cohort	Pooled analysis: individual patient data	2: CPRD; OPCR	
45	Turner S, Richardson K, Murray C, et al. Long-Acting $\beta$ -Agonist in Combination or Separate Inhaler as Step-Up Therapy for Children with Uncontrolled Asthma Receiving Inhaled Corticosteroids. <i>J allergy Clin Immunol Pract</i> 2017;5:99-106.e3	10.1016/j.jaip.2016.06.9	Drug comparative effectiveness	Analytical	Cohort	Pooled analysis: individual patient data	2: CPRD; OPCR	
46	Tyrstrup M, van der Velden A, Engstrom S, et al. Antibiotic prescribing in relation to diagnoses and consultation rates in Belgium, the Netherlands and Sweden: use of European quality indicators. <i>Scand J Prim Health Care</i> 2017;35:10–8	10.1080/02813432.2017.1288680	Health services research	Descriptive	Cross-sectional	Data not combined	3: Intego; Jonkoping County; Julius (Mondriaan)	
47	Uddin MJ, Groenwold RHH, de Boer A, et al. Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: a study of inhaled long-acting beta2-agonist use and the risk of myocardial infarction. <i>Pharmacoepidemiol Drug Saf</i> 2016;25 Suppl 1:132–41	10.1002/pds.3860	Drug safety	Analytical	Cohort	Pooled analysis: individual patient data	2: CPRD; NPCRD (Mondriaan)	
48	Uddin MJ, Groenwold RHH, de Boer A, et al. Instrumental variables analysis using multiple databases: an example of antidepressant use and risk of hip fracture. <i>Pharmacoepidemiol Drug Saf</i> 2016;25 Suppl 1:122–31	10.1002/pds.3863	Drug safety	Analytical	Cohort	Pooled analysis: individual patient data	3: BIFAP; NPCRD (Mondriaan); THIN	
49	Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QRResearch and CPRD databases. <i>BMJ</i> 2015;350:h2135	10.1136/bmj.h2135	Drug safety	Analytical	Case-control	Meta-analysis: fixed & random effects	2: CPRD; QRResearch	
50	Hippisley-Cox J, Coupland C, Brindle P. The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study. <i>BMJ Open</i> 2014;4:e005809	10.1136/bmjopen-2014-005809	Disease risk prediction	Descriptive	Cohort	Data not combined	2: CPRD; QRResearch	
51	Kostev K, Jockwig A, Hallwachs A, et al. Prevalence and risk factors of neuropathy in newly diagnosed type 2 diabetes in primary care practices: a retrospective database analysis in Germany and UK. <i>Prim Care Diabetes</i> 2014;8:250–5	10.1016/j.pcd.2014.01.11	Disease epidemiology	Analytical	Cohort	Data not combined	2: Disease Analyzer (Germany); Disease Analyzer (UK)	
52	Kostev K, Rathmann W. Influence of macro- and microvascular comorbidity on time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany, France, and UK. <i>Prim Care Diabetes</i> 2013;7:167–71	10.1016/j.pcd.2013.02.001	Drug utilization	Analytical	Cohort	Data not combined	3: Disease Analyzer (France); Disease Analyzer (Germany); Disease Analyzer (UK)	
54	Masclee GMC, Coloma PM, de Wilde M, et al. The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off. <i>Aliment Pharmacol Ther</i> 2014;39:1321–30	10.1111/apt.12759	Disease epidemiology	Descriptive	Cohort	Data not combined	2: IPCI; THIN	
55	Masclee GMC, Valkhoff VE, van Soest EM, et al. Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice? <i>Aliment Pharmacol Ther</i> 2013;38:178–89	10.1111/apt.12348	Drug safety	Analytical	Case-control	Multiple: pooled IPD + meta-analysis (RE)	3: CPRD; HSD (Italy); IPCI	
56	de Jonge L, Garne E, Gini R, et al. Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROMediCAT Study. <i>Drug Saf</i> 2015;38:1083–93	10.1007/s40264-015-0321-9	Disease epidemiology	Descriptive	Cohort	Data not combined	5: AHC (Mondriaan); BIFAP; CPRD; NPCRD (Mondriaan); THIN	2

Study ID <sup>a</sup>	Citation	Resource locator: [doi unless specified otherwise] <sup>b</sup>	Study topic	Study type	Study design <sup>c</sup>	Data combining	Primary care EHR data sources <sup>d</sup>	Other sources (if applicable)
57	Ruigómez A, Brauer R, Rodríguez LAG, et al. Ascertainment of acute liver injury in two European primary care databases. <i>Eur J Clin Pharmacol</i> 2014;70:1227–35	10.1007/s00228-014-1721-y	Disease epidemiology	Descriptive	Cohort	Data not combined	2: BIFAP; CPRD	
58	Thomas SL, Minassian C, Ganesan V, et al. Chickenpox and risk of stroke: A self-controlled case series analysis. <i>Clin Infect Dis</i> 2014;58:61–8	10.1093/cid/cit659	Disease epidemiology	Analytical	SCCS	Multiple: pooled IPD + meta-analysis (RE + FE)	4: CPRD; Disease Analyzer (UK); QResearch; THIN	
59	Trifiro G, Mokhles MM, Dieleman JP, et al. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested Case-control. <i>Drug Saf</i> 2012;35:159–71	10.2165/11594940-000000000-00000	Drug safety	Analytical	Case-control	Pooled analysis: individual patient data	3: HSD (Italy); IPCI; THIN	
60	Valkhoff VE, van Soest EM, Masclee GMC, et al. Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal - a 617,400-patient study. <i>Aliment Pharmacol Ther</i> 2012;36:790–9	10.1111/apt.12028	Drug utilization	Descriptive	Cohort	Data not combined	3: CPRD; HSD (Italy); IPCI	
61	Valkhoff VE, Coloma PM, Masclee GMC, et al. Validation study in four health-care databases: Upper gastrointestinal bleeding misclassification affects precision but not magnitude of drug-related upper gastrointestinal bleeding risk. <i>J Clin Epidemiol</i> 2014;67:921–31	10.1016/j.jclinepi.2014.02.020	Methodology / data quality	Analytical	Cohort	Pooled analysis: individual patient data	2: HSD (Italy); IPCI	2
62	Valkhoff VE, Schade R, 't Jong GW, et al. Population-based analysis of non-steroidal anti-inflammatory drug use among children in four European countries in the SOS project: what size of data platforms and which study designs do we need to assess safety issues? <i>BMC Pediatr</i> 2013;13:192	10.1186/1471-2431-13-192	Drug utilization	Descriptive	Cohort	Pooled analysis: semi-aggregate data	3: IPCI; Pédianet; THIN	4
63	Valkhoff VE, van Soest EM, Mazzaglia G, et al. Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events: a population-based study. <i>Arthritis Rheum</i> 2012;64:2792–802	10.1002/art.34433	Drug safety	Analytical	Case-control	Multiple: pooled IPD + meta-analysis (RE)	3: CPRD; HSD (Italy); IPCI	
64	Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case-control studies using two primary-care databases. <i>Br J Cancer</i> 2013;109:795–806	10.1038/bjc.2013.383	Drug safety	Analytical	Case-control	Meta-analysis: fixed effects	2: CPRD; QResearch	
66	Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data. <i>BMJ</i> 2013;346:f114	10.1136/bmj.f114	Drug safety	Analytical	Case-control	Meta-analysis: fixed effects	2: CPRD; QResearch	
67	Bremner SA, Carey IM, DeWilde S, et al. Infections presenting for clinical care in early life and later risk of hay fever in two UK birth cohorts. <i>Allergy</i> 2008;63:274–83	10.1111/j.1398-9995.2007.01599.x	Disease epidemiology	Analytical	Case-control	Meta-analysis: fixed effects	2: CPRD; DIN	
68	Cooper C, Steinbuch M, Stevenson R, et al. The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK. <i>Osteoporos Int</i> 2010;21:569–77	10.1007/s00198-009-1003-1	Disease epidemiology	Analytical	Case-control	Pooled analysis: individual patient data	2: CPRD; THIN	
69	De Clercq E, Van Casteren V, Jonckheer P, et al. Electronic Patient Record data as proxy of GPs' thoughts. <i>Stud Health Technol Inform</i> 2008;141:103–10	10.3233/978-1-58603-922-6-103	Methodology / data quality	Descriptive	Other	Data not combined	3: Resoprim (x3 networks)	
70	Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. <i>Heart</i> 2008;94:34–9	10.1136/hrt.2007.134890	Disease risk prediction	Descriptive	Cohort	Data not combined	2: QResearch; THIN	
71	Hippisley-Cox J, Coupland C. Individualising the risks of statins in men and women in England and Wales: population-based Cohort. <i>Heart</i> 2010;96:939–47	10.1136/hrt.2010.199034	Disease risk prediction	Analytical	Cohort	Data not combined	2: QResearch; THIN	
72	Hippisley-Cox J, Coupland C. Predicting the risk of chronic Kidney Disease in men and women in England and Wales: prospective derivation and external validation of the QKidney Scores. <i>BMC Fam Pract</i> 2010;11:49	10.1186/1471-2296-11-49	Disease risk prediction	Analytical	Cohort	Data not combined	2: QResearch; THIN	
73	Hsia Y, Neubert A, Sturkenboom MCJM, et al. Comparison of antiepileptic drug prescribing in children in three European countries. <i>Epilepsia</i> 2010;51:789–96	10.1111/j.1528-1167.2009.02331.x	Drug utilization	Descriptive	Cohort	Pooled analysis: semi-aggregate data	3: Disease Analyzer (UK); IPCI; Pédianet	
74	Molokhia M, McKeigue P, Curcin V, et al. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. <i>PLoS One</i> 2008;3:e2522	10.1371/journal.pone.0002522	Drug safety	Analytical	CCX	Data not combined	2: Mediplus; THIN	

Study ID <sup>a</sup>	Citation	Resource locator: [doi unless specified otherwise] <sup>b</sup>	Study topic	Study type	Study design <sup>c</sup>	Data combining	Primary care EHR data sources <sup>d</sup>	Other sources (if applicable)
75	Neubert A, Verhamme K, Murray ML, et al. The prescribing of analgesics and non-steroidal anti-inflammatory drugs in paediatric primary care in the UK, Italy and the Netherlands. <i>Pharmacol Res</i> 2010;62:243–8	10.1016/j.phrs.2010.04.006	Drug utilization	Descriptive	Cohort	Data not combined	3: Disease Analyzer (UK); IPCI; Pédianet	
76	Pfeil N, Uhlig U, Kostev K, et al. Antiemetic medications in children with presumed infectious gastroenteritis—pharmacoepidemiology in Europe and Northern America. <i>J Pediatr</i> 2008;153:659–62, 662.e1-3	10.1016/j.jpeds.2008.07.50	Drug utilization	Descriptive	Cohort	Data not combined	3: Disease Analyzer (France); Disease Analyzer (Germany); Disease Analyzer (UK)	2
77	Sturkenboom MCJM, Dieleman JP, Picelli G, et al. Prevalence and treatment of hypertensive patients with multiple concomitant cardiovascular risk factors in The Netherlands and Italy. <i>J Hum Hypertens</i> 2008;22:704–13	10.1038/jh.2008.82	Disease epidemiology	Descriptive	Cohort	Data not combined	2: HSD (Italy); IPCI	
78	Sturkenboom MCJM, Verhamme KMC, Nicolosi A, et al. Drug use in children: Cohort in three European countries. <i>BMJ</i> 2008;337:a2245–a2245	10.1136/bmj.a2245	Drug utilization	Descriptive	Cohort	Pooled analysis: semi-aggregate data	3: Disease Analyzer (UK); IPCI; Pédianet	
79	van Soest EM, Valkhoff VE, Mazzaglia G, et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. <i>Gut</i> 2011;60:1650–9	10.1136/gut.2011.239848	Drug safety	Analytical	Case-control	Pooled analysis: individual patient data	3: CPRD; HSD (Italy); IPCI	
80	van Staa TP, Sprafka JM. Study of adverse outcomes in women using testosterone therapy. <i>Maturitas</i> 2009;62:76–80	10.1016/j.maturitas.2008.11.001	Drug safety	Analytical	Cohort	Pooled analysis: individual patient data	2: CPRD; THIN	
81	Brankin E, Walker M, Lynch N, et al. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. <i>Curr Med Res Opin</i> 2006;22:1249–56	10.1185/030079906X112688	Drug utilization	Analytical	Cohort	Data not combined	3: CPRD; DIN; Disease Analyzer (UK)	
82	Bremner SA, Carey IM, DeWilde S, et al. Early-life exposure to antibacterials and the subsequent development of hayfever in childhood in the UK: case-control studies using the General Practice Research Database and the Doctors' Independent Network. <i>Clin Exp Allergy</i> 2003;33:1518–25	10.1046/j.1365-2222.2003.01794.x	Disease epidemiology	Analytical	Case-control	Meta-analysis: fixed effects	2: CPRD; DIN	
83	Bremner SA, Carey IM, DeWilde S, et al. Timing of routine immunisations and subsequent hay fever risk. <i>Arch Dis Child</i> 2005;90:567–73	10.1136/adc.2004.051714	Disease epidemiology	Analytical	Case-control	Meta-analysis: fixed effects	2: CPRD; DIN	
84	Bremner SA, Carey IM, DeWilde S, et al. Vaccinations, infections and antibacterials in the first grass pollen season of life and risk of later hayfever. <i>Clin Exp Allergy</i> 2007;37:512–7	10.1111/j.1365-2222.2007.02697.x	Disease epidemiology	Analytical	Case-control	Meta-analysis: fixed effects	2: CPRD; DIN	
86	Carey IM, Cook DG, De Wilde S, et al. Implications of the problem orientated medical record (POMR) for research using electronic GP databases: a comparison of the Doctors Independent Network Database (DIN) and the General Practice Research Database (GPRD). <i>BMC Fam Pract</i> 2003;4:14	10.1186/1471-2296-4-14	Methodology / data quality	Descriptive	Cohort	Data not combined	2: CPRD; DIN	
88	De Wilde S, Carey IM, Bremner SA, et al. A comparison of the recording of 30 common childhood conditions in the Doctor's Independent Network and General Practice Research Databases. <i>Heal Stat Q</i> 2004;21–31	pmid:15704391	Methodology / data quality	Descriptive	Cohort	Data not combined	2: CPRD; DIN	
89	Hernández-Díaz S, García Rodríguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. <i>BMC Med</i> 2006;4:22	10.1186/1741-7015-4-22	Drug safety	Descriptive	Cohort	Data not combined	2: BIFAP; CPRD	
90	Jordan K, Clarke AM, Symmons DPM, et al. Measuring disease prevalence: a comparison of musculoskeletal disease using four general practice consultation databases. <i>Br J Gen Pract</i> 2007;57:7–14	pmid:17244418	Disease epidemiology	Descriptive	Cohort	Data not combined	2: CPRD; CiPCA	2
93	Price DB, Gefen E, Gopalan G, et al. Real-life effectiveness and safety of salbutamol Steri-Neb™ vs. Ventolin Nebules® for exacerbations in patients with COPD: Historical Cohort. <i>PLoS One</i> 2018;13:e0191404	10.1371/journal.pone.0191404	Drug comparative effectiveness	Analytical	Cohort	Pooled analysis: individual patient data	2: CPRD; OPCR	
94	Abbing-Karahagopian V, Huerta C, Souverein PC, et al. Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. <i>Eur J Clin Pharmacol</i> 2014;70:849–57	10.1007/s00228-014-1676-z	Drug utilization	Descriptive	Cohort	Data not combined	5: AHC (Mondriaan); BIFAP; CPRD; NPCRD (Mondriaan); THIN	2

Study ID <sup>a</sup>	Citation	Resource locator: [doi unless specified otherwise] <sup>b</sup>	Study topic	Study type	Study design <sup>c</sup>	Data combining	Primary care EHR data sources <sup>d</sup>	Other sources (if applicable)
101	Charlton RA, Jordan S, Pierini A, et al. Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy: a population-based study in six European regions. <i>BJOG</i> 2015;122:1010–20	10.1111/1471-0528.13143	Drug utilization	Descriptive	Cohort	Data not combined	2: CPRD; SAIL	4
102	Coloma PM, de Ridder M, Bezemer I, et al. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country Case-control. <i>Osteoporos Int</i> 2016;27:1857–67	10.1007/s00198-015-3441-2	Drug safety	Analytical	Case-control	Multiple: pooled IPD + meta-analysis (RE + FE)	3: HSD (Italy); IPCI; THIN	3
103	Coloma PM, Schuemie MJ, Trifirò G, et al. Drug-induced acute myocardial infarction: identifying 'prime suspects' from electronic healthcare records-based surveillance system. <i>PLoS One</i> 2013;8:e72148	10.1371/journal.pone.0072148	Methodology / data quality	Analytical	Cohort	Pooled analysis: individual patient data	3: HSD (Italy); IPCI; Pédianet	4
104	Coloma PM, Trifirò G, Schuemie MJ, et al. Electronic healthcare databases for active drug safety surveillance: is there enough leverage?. <i>Pharmacoepidemiol Drug Saf</i> 2012;21:611–21	10.1002/pds.3197	Drug safety	Descriptive	Cohort	Pooled analysis: semi-aggregate data	4: HSD (Italy); IPCI; Pédianet; QResearch	4
105	de Bie S, Coloma PM, Ferrajolo C, et al. The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective Cohort. <i>Br J Clin Pharmacol</i> 2015;80:304–14	10.1111/bcp.12610	Drug safety	Descriptive	Cohort	Pooled analysis: semi-aggregate data	3: HSD (Italy); IPCI; Pédianet	4
106	de Groot MCH, Klungel OH, Leufkens HGM, et al. Sources of heterogeneity in case-control studies on associations between statins, ACE-inhibitors, and proton pump inhibitors and risk of pneumonia. <i>Eur J Epidemiol</i> 2014;29:767–75	10.1007/s10654-014-9941-0	Drug safety	Analytical	Case-control	Data not combined	3: AHC (Mondriaan); LRGP; NPCRD (Mondriaan)	2
107	de Groot MCH, Schuerch M, de Vries F, et al. Antiepileptic drug use in seven electronic health record databases in Europe: a methodologic comparison. <i>Epilepsia</i> 2014;55:666–73	10.1111/epi.12557	Drug utilization	Descriptive	Cohort	Data not combined	5: AHC (Mondriaan); BIFAP; CPRD; NPCRD (Mondriaan); THIN	2
108	Ferrajolo C, Coloma PM, Verhamme KMC, et al. Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network. <i>Drug Saf</i> 2014;37:99–108	10.1007/s40264-013-0132-9	Drug safety	Analytical	Multiple: cohort; SCCS	Pooled analysis: individual patient data	3: HSD (Italy); IPCI; Pédianet	4
110	Huerta C, Abbing-Karahagopian V, Requena G, et al. Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. <i>Pharmacoepidemiol Drug Saf</i> 2016;25 Suppl 1:56–65	10.1002/pds.3825	Drug utilization	Descriptive	Cohort	Data not combined	5: AHC (Mondriaan); BIFAP; CPRD; NPCRD (Mondriaan); THIN	2
111	Korhonen P, Heintjes EM, Williams R, et al. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective Cohort using datasets from four European countries. <i>BMJ</i> 2016;354:i3903	10.1136/bmj.i3903	Drug safety	Analytical	Cohort	Multiple: pooled IPD + meta-analysis (RE + FE)	2: CPRD; PHARMO GP	3
112	LoCasale R, Kern DM, Chevalier P, et al. Description of cardiovascular event rates in patients initiating chronic opioid therapy for noncancer pain in observational cohort studies in the US, UK, and Germany. <i>Adv Ther</i> 2014;31:708–23	10.1007/s12325-014-0131-y	Drug safety	Descriptive	Cohort	Data not combined	2: CPRD; Disease Analyzer (Germany)	1
113	Masclee GMC, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. <i>Gastroenterology</i> 2014;147:784-792.e9	10.1053/j.gastro.2014.06.7	Drug safety	Analytical	SCCS	Multiple: pooled IPD + meta-analysis (RE)	3: HSD (Italy); IPCI; Pédianet	4
114	Mokhles MM, Trifirò G, Dieleman JP, et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease. <i>Pharmacol Res</i> 2012;65:358–64	10.1016/j.phrs.2011.11.009	Drug safety	Analytical	Case-control	Multiple: pooled IPD + meta-analysis (RE + FE)	3: HSD (Italy); IPCI; THIN	1
115	Rottenkolber M, Voogd E, van Dijk L, et al. Seasonal changes in prescribing of long-acting beta-2-agonists-containing drugs. <i>Respir Med</i> 2015;109:828–37	10.1016/j.rmed.2015.01.010	Drug utilization	Descriptive	Cohort	Data not combined	5: AHC (Mondriaan); BIFAP; CPRD; NPCRD	1



Study ID <sup>a</sup>	Citation	Resource locator: [doi unless specified otherwise] <sup>b</sup>	Study topic	Study type	Study design <sup>c</sup>	Data combining	Primary care EHR data sources <sup>d</sup>	Other sources (if applicable)
							(Mondriaan ); THIN	
116	Rottenkolber M, Voogd E, van Dijk L, et al. Time trends of period prevalence rates of patients with inhaled long-acting beta-2-agonists-containing prescriptions: a European comparative database study. <i>PLoS One</i> 2015;10:e0117628	10.1371/journal.pone.0117628	Drug utilization	Descriptive	Cohort	Data not combined	5: AHC (Mondriaan); BIFAP; CPRD; NPCRD (Mondriaan); THIN	2
117	Trifirò G, de Ridder M, Sultana J, et al. Use of azithromycin and risk of ventricular arrhythmia. <i>CMAJ</i> 2017;189:E560–8	10.1503/cmaj.160355	Drug safety	Analytical	Case-control	Multiple: pooled IPD + meta-analysis (RE)	3: HSD (Italy); IPCI; THIN	4
118	Tyczynski JE, Oleske DM, Klingman D, et al. Safety assessment of an anti-obesity drug (sibutramine): a retrospective Cohort. <i>Drug Saf</i> 2012;35:629–44	10.2165/11599220-000000000-00000	Drug safety	Analytical	Cohort	Data not combined	2: Disease Analyzer (Germany); Disease Analyzer (UK)	
119	Coloma PM, Schuemie MJ, Trifirò G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. <i>Pharmacoepidemiol Drug Saf</i> 2011;20:1–11	10.1002/pds.2053	Drug safety	Analytical	Cohort	Data not combined	4: HSD (Italy); IPCI; Pedianet; QResearch	4
121	Sen EF, Verhamme KMC, Neubert A, et al. Assessment of pediatric asthma drug use in three European countries; a TEDDY study. <i>Eur J Pediatr</i> 2011;170:81–92	10.1007/s00431-010-1275-7	Drug utilization	Descriptive	Cohort	Data not combined	3: Disease Analyzer (UK); IPCI; Pedianet	
122	Cainzos-Achirica M, Varas-Lorenzo C, Pottegård A, et al. Methodological challenges when evaluating potential off-label prescribing of drugs using electronic health care databases: A case study of dabigatran etexilate in Europe. <i>Pharmacoepidemiol Drug Saf</i> 2018;27:713–23	10.1002/pds.4416	Drug utilization	Descriptive	Cross-sectional	Data not combined	2: CPRD; LPD (France)	1
124	Martin-Merino E, Petersen I, Hawley S, et al. Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK. <i>Osteoporos Int</i> 2018;29:467–78	10.1007/s00198-017-4308-5	Drug safety	Analytical	Cohort	Data not combined	2: BIFAP; CPRD	
125	Anyanwagu U, Owen K, Mamza J, et al. Demographics, insulin use and clinical targets in type 2 diabetes insulin users: comparison of a local integrated diabetes service vs a UK-wide cohort. <i>Pract Diabetes</i> 2017;34:123–8	10.1002/pdi.2099	Health services research	Descriptive	Cross-sectional	Data not combined	2: EIDS; THIN	
127	Chiquette E, Oral EA, Garg A, et al. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. <i>Diabetes Metab Syndr Obes</i> 2017;10:375–83	10.2147/DMSO.S130810	Disease epidemiology	Descriptive	Cross-sectional	Data not combined	2: CPRD; Humedica	2
128	Lo Re V, Carbonari DM, Saine ME, et al. Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. <i>BMJ open diabetes Res care</i> 2017;5:e000400	10.1136/bmjdr-2017-000400	Drug safety	Analytical	Cohort	Meta-analysis: method not specified	2: CPRD; THIN	2
129	Price D, Thomas V, von Ziegenweid J, et al. Switching patients from other inhaled corticosteroid devices to the Easyhaler®: historical, matched-Cohort of real-life asthma patients. <i>J Asthma Allergy</i> 2014;7:31–51	10.2147/JAA.S59386	Drug comparative effectiveness	Analytical	Cohort	Pooled analysis: individual patient data	2: CPRD; OPCRD	
134	Coloma PM, Valkhoff VE, Mazzaglia G, et al. Identification of acute myocardial infarction from electronic healthcare records using different disease coding systems: a validation study in three European countries. <i>BMJ Open</i> 2013;3:e002862	10.1136/bmjopen-2013-002862	Drug safety	Analytical	Cohort	Pooled analysis: individual patient data	2: HSD (Italy); IPCI	1
135	Mor A, Frøslev T, Thomsen RW, et al. Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO project. <i>Infection</i> 2015;43:453–72	10.1007/s15010-015-0768-8	Drug utilization	Descriptive	Cohort	Data not combined	2: HSD (Italy); THIN	4
136	Poluzzi E, Diemberger I, De Ridder M, et al. Use of antihistamines and risk of ventricular tachyarrhythmia: a nested Case-control in five European countries from the ARITMO project. <i>Eur J Clin Pharmacol</i> 2017;73:1499–510	10.1007/s00228-017-2317-0	Drug safety	Analytical	Case-control	Multiple: pooled IPD + meta-analysis (RE)	3: HSD (Italy); IPCI; THIN	4
137	Roberto G, Leal I, Sattar N, et al. Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project. <i>PLoS One</i> 2016;11:e0160648	10.1371/journal.pone.0160648	Methodology / data quality	Other	Cross-sectional	Data not combined	3: HSD (Italy); IPCI; THIN	5

Study ID <sup>a</sup>	Citation	Resource locator: [doi unless specified otherwise] <sup>b</sup>	Study topic	Study type	Study design <sup>c</sup>	Data combining	Primary care EHR data sources <sup>d</sup>	Other sources (if applicable)
138	La Gamba F, Corrao G, Romio S, et al. Combining evidence from multiple electronic health care databases: performances of one-stage and two-stage meta-analysis in matched case-control studies. <i>Pharmacoepidemiol Drug Saf</i> 2017;26:1213–9	10.1002/pds.4280	Drug safety	Analytical	Case-control	Multiple: pooled IPD + meta-analysis (FE)	2: IPCI; THIN	1

<sup>a</sup> Record identifier used in reference management, and different from reference number used in main study text.

<sup>b</sup> If digital object identifier [doi] was not available, Pubmed ID [pmid] was used

<sup>c</sup> SCCS – self controlled case series; CCX – case crossover:

<sup>d</sup> See Table S2 for further details of primary care EHR data sources

Table S2: Summary details of primary care electronic health record (EHR) data sources used in studies included in systematic review.

Data Source ID	Short name	Source Name	Country	Clinical Coding	Drug Coding	Source reference	Resource locator <sup>a</sup>
1	CPRD	Clinical Practice Research Datalink	UK	Read V2	DM+D	<a href="https://www.ncbi.nlm.nih.gov/pubmed/26050254">https://www.ncbi.nlm.nih.gov/pubmed/26050254</a>	doi: 10.1093/ije/dyv098
2	THIN	The Health Information Network	UK	Read V2	DM+D	<a href="https://www.ncbi.nlm.nih.gov/pubmed/22828580">https://www.ncbi.nlm.nih.gov/pubmed/22828580</a>	doi: 10.14236/jhi.v19i4.820
3	QRResearch	QRResearch	UK	Read V2 / SNOMED-CT	DM+D	<a href="https://bmjopen.bmj.com/content/5/9/e008503.long">https://bmjopen.bmj.com/content/5/9/e008503.long</a>	doi:10.1136/bmjopen-2015-008503
4	IPCI	Integrated Primary Care Information database	Netherlands	ICPC	ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/10805025">https://www.ncbi.nlm.nih.gov/pubmed/10805025</a>	doi:10.1055/s-0038-1634402
5	Pedinet	PediaNet	Italy		ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/15930187">https://www.ncbi.nlm.nih.gov/pubmed/15930187</a>	doi:10.1542/peds.2004-0040
7	SAIL	SAIL Databank	UK	Mixed	DM+D	<a href="http://www.ncbi.nlm.nih.gov/pubmed/19732426">http://www.ncbi.nlm.nih.gov/pubmed/19732426</a>	doi:10.1186/1472-6963-9-157
8	LPD (France)	Cegedim LPD (Longitudinal Patient Data): France	France	ICD-9/10 CM	ATC	<a href="https://epidemiologie-france.aviesan.fr/en/ccontent/pdf/(ObjectId)/91221">https://epidemiologie-france.aviesan.fr/en/ccontent/pdf/(ObjectId)/91221</a>	url: <a href="https://epidemiologie-france.aviesan.fr/en/ccontent/pdf/(ObjectId)/91221">https://epidemiologie-france.aviesan.fr/en/ccontent/pdf/(ObjectId)/91221</a>
9	NPCRD (Mondriaan)	Netherlands Primary Care Research Database (NPCRD)	Netherlands	ICPC/ICD	ATC	<a href="http://www.ncbi.nlm.nih.gov/pubmed/25154551">http://www.ncbi.nlm.nih.gov/pubmed/25154551</a>	doi:10.1016/s1098-3015(10)74933-0
11	BIFAP	Spanish Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP)	Spain	ICPC	ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/25066450">https://www.ncbi.nlm.nih.gov/pubmed/25066450</a>	doi:10.1007/s00228-012-1386-3
12	HSD (Italy)	Health Search Database (Italy)	Italy	ICD-9 CM	ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/24816637">https://www.ncbi.nlm.nih.gov/pubmed/24816637</a>	doi:10.1371/journal.pone.0095419
15	AHC (Mondriaan)	Mondriaan Almere Healthcare group (AHC) database	Netherlands	ICPC/ICD	ATC	<a href="https://www.valueinhealthjournal.com/article/S1098-3015(10)74933-0/abstract">https://www.valueinhealthjournal.com/article/S1098-3015(10)74933-0/abstract</a>	doi:10.1016/s1098-3015(10)74933-0
17	SIDIAP	Sistema de Información para el desarrollo de la Investigación en Atención Primaria	Spain	ICD-10	ATC	<a href="http://www.sidiap.org">http://www.sidiap.org</a>	url: <a href="http://www.sidiap.org">http://www.sidiap.org</a>
25	CDARS	Hong Kong Clinical Data Analysis and Reporting System database	Hong Kong	ICD-9 CM		<a href="https://www.ncbi.nlm.nih.gov/pubmed/24833754">https://www.ncbi.nlm.nih.gov/pubmed/24833754</a>	doi:10.1093/jac/dku145
26	ResearchOne	ResearchOne	UK	CTV3	DM+D	<a href="https://www.ncbi.nlm.nih.gov/pubmed/26944937">https://www.ncbi.nlm.nih.gov/pubmed/26944937</a>	url: <a href="http://www.researchone.org/">http://www.researchone.org/</a>
28	Julius (Mondriaan)	Julius Primary Care Network Database	Netherlands		ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/30253760">https://www.ncbi.nlm.nih.gov/pubmed/30253760</a>	doi:10.1016/s1098-3015(10)74933-0
29	NWEH-LDB	NorthWest EHealth linked database	UK	Read V2/SNOMED-CT	DM+D	<a href="https://bmcmmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-015-0132-z">https://bmcmmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-015-0132-z</a>	doi:10.1186/s12911-015-0132-z
30	OCHIN Clarity (Epic EHR)	Oregon Community Health Information Network (OCHIN)	USA	ICD-9 CM	ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/26934626">https://www.ncbi.nlm.nih.gov/pubmed/26934626</a>	doi:10.7812/TPP/15-081
31	KP Clarity (Epic EHR)	Kaiser Permanente Epic EHR Clarity database	USA	ICD-9 CM	ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/26934626">https://www.ncbi.nlm.nih.gov/pubmed/26934626</a>	doi:10.7812/TPP/15-081
32	OPCRD	Optimum Patient Care Research Database (OPCRD)	UK	Read V2	DM+D	<a href="https://optimumpatientcare.org/database-overview/">https://optimumpatientcare.org/database-overview/</a>	url: <a href="https://optimumpatientcare.org/database-overview/">https://optimumpatientcare.org/database-overview/</a>
33	LPD (Spain)	IMS Longitudinal Patient Database (Spain)	Spain	ICD-9/10 CM	ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/27155295">https://www.ncbi.nlm.nih.gov/pubmed/27155295</a>	doi:10.1111/ejh.12776
34	LPD (Germany)	IMS Longitudinal Patient Database (Germany)	Germany	ICD-9/10 CM	ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/27155295">https://www.ncbi.nlm.nih.gov/pubmed/27155295</a>	doi:10.1111/ejh.12776
35	LPD (Belgium)	IMS Longitudinal Patient Database (Belgium)	Belgium	ICD-9/10 CM	ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/27155295">https://www.ncbi.nlm.nih.gov/pubmed/27155295</a>	doi:10.1111/ejh.12776
39	SIR	Salford Integrated Record (SIR)	UK	Read V2	DM+D	<a href="https://www.ncbi.nlm.nih.gov/pubmed/25481707">https://www.ncbi.nlm.nih.gov/pubmed/25481707</a>	doi:10.1007/s00125-014-3456-9
41	Disease Analyzer (Germany)	IMS Disease Analyzer (Germany)	Germany	ICD-10	ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/19825325">https://www.ncbi.nlm.nih.gov/pubmed/19825325</a>	doi:10.5414/cpp47617
42	Disease Analyzer (France)	IMS Disease Analyzer (France)	France	ICD-10	ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/19825325">https://www.ncbi.nlm.nih.gov/pubmed/19825325</a>	doi:10.5414/cpp47617

Data Source ID	Short name	Source Name	Country	Clinical Coding	Drug Coding	Source reference	Resource locator <sup>a</sup>
46	Disease Analyzer (UK)	IMS Disease Analyzer (UK)	UK	ICD-10	ATC	<a href="https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2125.2005.02450.x">https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2125.2005.02450.x</a>	<a href="https://doi.org/10.1111/j.1365-2125.2005.02450.x">doi:10.1111/j.1365-2125.2005.02450.x</a>
51	DIN	Doctors' Independent Network (DIN)	UK	Read V2	BNF	<a href="https://www.ncbi.nlm.nih.gov/pubmed/15171985">https://www.ncbi.nlm.nih.gov/pubmed/15171985</a>	<a href="https://doi.org/10.1016/j.ijmedinf.2004.02.002">doi:10.1016/j.ijmedinf.2004.02.002</a>
52	Intego	Intego Network	Belgium	ICPC	ATC	<a href="http://www.ncbi.nlm.nih.gov/pubmed/24906941">http://www.ncbi.nlm.nih.gov/pubmed/24906941</a>	<a href="https://doi.org/10.1186/1472-6947-14-48">doi:10.1186/1472-6947-14-48</a>
53	Jonkoping County	Jonkoping County Primary Care Database	Sweden	ICD-10	ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/28277045">https://www.ncbi.nlm.nih.gov/pubmed/28277045</a>	<a href="https://doi.org/10.1080/02813432.2017.1288680">doi:10.1080/02813432.2017.1288680</a>
58	Resoprim	Resoprim Project	Belgium	ICPC	ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/18953130">https://www.ncbi.nlm.nih.gov/pubmed/18953130</a>	<a href="https://doi.org/10.3233/978-1-58603-922-6-103">doi:10.3233/978-1-58603-922-6-103</a>
59	Mediplus	IMS Mediplus	UK	Read V2	BNF	<a href="https://www.ncbi.nlm.nih.gov/pubmed/16368704">https://www.ncbi.nlm.nih.gov/pubmed/16368704</a>	<a href="https://doi.org/10.1093/fampra/cmi106">doi:10.1093/fampra/cmi106</a>
62	CiPCA	Consultations in Primary Care Archive	UK	Read V2	BNF	<a href="https://www.keele.ac.uk/mrr/cipcdatabase/">https://www.keele.ac.uk/mrr/cipcdatabase/</a>	<a href="https://doi.org/10.1159/000052402">url:https://www.keele.ac.uk/mrr/cipcdatabase/</a>
65	THALES	THALES Database	France	ICD-9 CM	ATC	<a href="http://www.ncbi.nlm.nih.gov/pubmed/11111209">http://www.ncbi.nlm.nih.gov/pubmed/11111209</a>	<a href="https://doi.org/10.1159/000052402">doi:10.1159/000052402</a>
72	LRGP	Leidsche Rijn GP database (Mondriaan)	Netherlands	ICPC	ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/15921047">https://www.ncbi.nlm.nih.gov/pubmed/15921047</a>	<a href="https://doi.org/10.1007/s10654-004-5689-2">doi:10.1007/s10654-004-5689-2</a>
74	PHARMO GP	PHARMO GP database	Netherlands	ICPC	ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/27530399">https://www.ncbi.nlm.nih.gov/pubmed/27530399</a>	<a href="https://doi.org/10.1136/bmj.i3903">doi:10.1136/bmj.i3903</a>
76	EIDS	Erewash (Integrated) Diabetes Service	UK	Read V2	DM+D	<a href="https://onlinelibrary.wiley.com/doi/full/10.1002/pdi.2099">https://onlinelibrary.wiley.com/doi/full/10.1002/pdi.2099</a>	<a href="https://doi.org/10.1002/pdi.2099">doi:10.1002/pdi.2099</a>
79	Humedica	Humedica NorthStar from Optum	USA	ICD-9 CM	ATC	<a href="https://www.nihcollaboratory.org/Pages/OptumInsight-MetaData-Table.aspx">https://www.nihcollaboratory.org/Pages/OptumInsight-MetaData-Table.aspx</a>	<a href="https://doi.org/10.2147/DMSO.S130810">doi:10.2147/DMSO.S130810</a>
80	GE Healthcare	GE Healthcare Database	USA	ICD-9 CM	ATC	<a href="https://www.ncbi.nlm.nih.gov/pubmed/29066925">https://www.ncbi.nlm.nih.gov/pubmed/29066925</a>	<a href="https://doi.org/10.2147/DMSO.S130810">doi:10.2147/DMSO.S130810</a>

<sup>a</sup> doi: Digital object identifier; url: Uniform resource locator